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MOLECULAR STAGING OF COLORECTAL CANCER:
K-RAS MUTATION ANALYSIS OF LYMPH NODES
UPSTAGES DUKES’ B2 PATIENTS

Jennifer S. Thebo, Ph.D.
Western Michigan University, 1998

The successful treatment of colorectal cancer depends upon the ability of
staging systems to identify patients who are at risk for recurrence. The currently used
systems fail in a significant number o f patients. Multiple attempts have been made to
improve upon these systems in order to provide better treatment for at-risk patients.
A variety of oncogenes and tumor suppressor genes have been implicated in
colorectal cancer. Mutations in one of these, K-ras, occur in 40-60% of colorectal
carcinomas.

However, the relationship between specific mutations and clinical

outcome is unclear.
The purpose of this study was to determine whether or not K-ras mutational
status of tumors from 97 colorectal cancer patients was associated with survival, and
to determine whether or not the K-ras mutational status of regional lymph nodes
could be used as a staging tool.
The group was divided into four cohorts according to survival (less than five
or greater than ten years) and modified Dukes’ classification (B2 and C2). The author
assessed techniques for DNA extraction and mutation detection. Tumor DNA was
screened for K-ras mutations using mutation-specific DNA amplification, followed
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by gel electrophoresis in a 96-well array. Dukes’ B2 patients with mutations were
further analyzed to determine whether or not the same mutations could be identified
in their lymph nodes.
Complete data was obtained for 89 patients (91.8%). Mutations were detected
in 49.4% of tumors (44/89). Analysis o f the mutations identified a group of 11
patients with concurrent mutations in codons 12 and 13, which was associated with
long-term survival. Mutational analysis of lymph nodes from Dukes B 2 patients with
mutation-positive tumors revealed an 80% (16/20) incidence of the same mutations in
regional lymph nodes. None of the four patients with mutation-free lymph nodes
developed recurrence compared to 37.5% (6/16) with K-ras positive lymph nodes.
The presence of concurrent mutations in codons 12 and 13 o f the K-ras gene
was a positive prognostic indicator in this group of patients. Mutational analysis of
lymph nodes identifies high-risk patients who should be considered for additional
treatment. Therefore, K-ras mutational analysis should be considered for molecular
staging o f colorectal cancer.
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CHAPTER I

COLORECTAL CANCER

Staging of Colorectal Cancer

With an age-standardized annual incidence rate for North America o f 10-32
cases per 100,000 (1), colorectal cancer (CRC) is the second most common cause of
cancer death (2). Treatment o f CRC relies upon the identification o f clinical and
pathological features. These features have been used to develop staging systems,
such as the Modified Dukes’ system of CRC classification (3). Summarized in Table
1, this system examines variations in the depth of tumor invasion, presence of lymph
node metastasis, and presence o f distant metastasis (4). However, this system fails to
identify all at-risk patients.

This is evidenced by lower than expected five-year

survival rates following curative colorectal resections in patients with no identified
metastasis (5).
The single most important prognostic factor affecting survival for patients
undergoing curative resections for CRC is the presence or absence o f regional lymph
node involvement (6). It is also prognostically important to identify the number of
regional lymph nodes containing metastatic deposits.

This is evidenced by data

generated by Cohen et al. (7), which show that 66% of patients with one to three
positive nodes survived five years compared to 37% of patients with four or more
1
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2
Table 1
Modified Dukes’ Staging System

Dukes’ Stage

Depth of Tumor
Invasion

Lymph Node
Metastasis

Distant
Metastasis

A

Mucosa/Submucosa

No

No

Bi

Confined to bowel wall

No

No

b2

Through bowel wall

No

No

Ci

Confined to bowel wall

Yes

No

c2

Through bowel wall

Yes

No

D

Any depth

Yes/No

Yes

positive nodes. The difficulty in providing this information is two-fold. First, the
mesentery must be appropriately evaluated so that a sufficient number of nodes can
be retrieved and examined by the pathologist.

Second, accurate identification o f

micrometastases, particularly in small nodes, remains a significant problem.
In addition to classical staging methods, it has been suggested that prognostic
markers be used in choosing treatment for colorectal cancer (8).

Several groups,

including the American Joint Committee on Cancer (AJCC), have worked to develop
recommendations for the use of prognostic markers.
The College of American Pathologists (CAP) recommended the routine
clinical use of prognostic markers in addition to classical staging criteria (9). They
divided prognostic markers into categories: (a) Category I—important prognostic
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markers which are widely used in patient management, (b) Category II—markers
which have been extensively studied and may be potentially useful, and (c) Category
HI—all others.
CAP Category I included histopathological markers such as venous invasion,
carcinoma within adenoma, tumor type, and tumor grade. Serum carcinoembryonic
antigen (CEA) was also included in this category. Category II included histological
evidence o f immune response and flow-cytometric analyses o f DNA ploidy and Sphase fraction.

Category III included flow cytometric analysis o f mitotic index,

serological markers other than CEA, cytokeratin staining, cytogenetic analyses, and
genetic markers (9).

Adenoma-Carcinoma Sequence

The adenoma-carcinoma sequence has become a well-accepted model for the
development of colorectal neoplasia (10). This model states that colorectal cancer
develops through a multi-step process that develops from normal epithelium through
hyperproliferative epithelium, adenoma, and carcinoma. The model is supported by
visible changes in physical structure of the developing neoplasia (11). Additional
support is found in the results o f flow cytometric analysis o f the DNA content of
colorectal adenomas and focal cancers (12).

These results indicate that DNA

aneuploidy in adenomas correlates with the DNA aneuploidy of the associated focal
cancers. However, adenomas not associated with focal cancers do not show DNA
aneuploidy. Changes in DNA ploidy correlated with increased size o f the developing
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4
polyp, further supporting the idea of the adenoma-carcinoma sequence.

Genetics o f Colorectal Cancer

The multi-step development o f CRC is also supported by a variety o f studies
involving tumor suppressor genes and oncogenes.

These studies suggest that

‘multiple hits’ are necessary for the development of CRC. Vogelstein et al. (13)
suggested a model that involves mutation or loss of the APC (adenomatous polyposis
coli) tumor suppressor gene, mutation of the K-ras gene, loss o f the DCC (deleted in
colon cancer) tumor suppressor gene, and loss of p53 tumor suppressor function.
Their model was supported by changes in mutation rates of these genes during tumor
progression. In addition to these changes, other, yet to be identified, alterations may
be responsible for metastatic potential o f CRC (11).
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CHAPTER II

THE K-RAS ONCOGENE

K-ras Structure and Function

The K-ras gene, located on chromosome 12, is part of a family o f genes that
encode 21 kDalton proteins (p21ras).

The p21ras proteins are members of a

superfamily of small GTPases that are involved in signal transduction and growth
control (14).
The ras proteins have two domains. The first domain binds GTP or GDP and
has GTPase activity (15). The protein cycles through an active GTP-bound form, and
an inactive GDP bound form.

This cycling is regulated by guanine nucleotide

exchange factors (GEFs) and GTPase activating proteins (GAPs) (16). The second
domain is at the C-terminus o f the protein, which is responsible for translocation of
ras to the plasma membrane (17).

Ras proteins must undergo a series of post-

translational modifications in order for this translocation to occur.

Modification

involves the addition o f a famesyl isoprenoid to the cysteine of the CAAX box,
followed by removal o f the AAX terminus and carboxymethylation o f the terminal
cysteine residue. The consensus C-terminal CAAX sequence is required for these
modifications to occur (14,17).
Ras proteins are involved in multiple signal-transduction pathways.
5
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One

pathway involves mediation o f signals from tyrosine kinase receptors following
stimulation by growth factors (18). A complex o f two proteins—SOS and Grb2,
mediates ras activation following tyrosine kinase receptor stimulation. In its active
GTP-bound form, ras is able to bind to and activate an effector, rafl (19). Activation
o f rafl triggers activation of the mitogen-activated protein kinase (MAPK) pathway.
Ultimately, this results in activation o f transcription factors and changes in gene
expression (20).
Mutant forms of ras produce significant changes in cellular growth. This is
attributed to either loss of GTPase activity or increased GDP/GTP exchange rates,
which result in higher steady state levels o f the GTP-bound form of the protein
(21,22). The net result of the most common mutant forms of ras is decreased intrinsic
hydrolysis rate o f GTP by 10-fold (21).

The K-ras Gene

The K-ras gene (Figure 1) is over 38 kilo-base pairs long and consists o f six
exons— la (also referred to as exon 0), 1, 2, 3, 4a, and 4b (23,24). The gene encodes
two isomorphic ras proteins as a result o f splicing of the alternate exons (4a or 4b).

Exon #
S’

H

Legend:

Figure 1.

0

l

n

H
11

2

3

HIH
HH
non b
h
= coding exons

4a

4b

H
mm

IH
un

1 1 = noncoding exon

|

j
= promoter

The K-ras Gene.
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The two forms, 188 and 189 amino acids long, differ only in their carboxy terminus.
The promoters lie immediately 5’ to exon la, which is noncoding (25).

K-ras

oncogenic activity results from single point mutations at codons 12, 13 (exon 1) or 61
(exon 2), resulting in amino acid substitutions (26). Since these amino acids are
located in the guanine nucleotide-binding domain o f the ras proteins, this results in
altered GTP binding or hydrolysis (17).

The K-ras Oncogene in Colorectal Cancer

The relationship between mutant forms o f ras and oncogenesis is supported by
a variety o f evidence. Mutant forms of ras have been associated with a variety of
human malignancies (26).

Also, the functional activities of mutant ras are

significantly different from normal ras protein, as evidenced by increased
proliferation upon introduction of mutant ras into cells (27-29). Finally, transgenic
mice with mutated ras exhibit a higher incidence of tumor development in the skin,
liver, pancreas, and lungs (30).
K-ras mutations occur in 9-10% of small adenomatous colon polyps, 40-50%
o f larger dysplastic polyps, and 40-60% of colonic cancers (13,31-33).

These

findings suggest that, while K-ras mutation is not the initiating step in the adenomacarcinoma sequence, it does occur fairly early in the progression (31,34,35).
Analysis o f K-ras mutations has been used to determine the clonal nature of
CRC. Dix et al. (36) examined 11 patients with colorectal tumors using K-ras and
p53 mutation analysis. Of the 11 patients, four had metastatic lesions of the lymph
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nodes and/or liver. In all patients, they found complete homogeneity in respect to the
mutations detected (i.e., the same mutation was found in adenoma, carcinoma, lymph
nodes, and liver).
Others have performed similar analysis, but with slightly different outcomes.
Giaretti et al. (37) found that, while the majority of tumors exhibited a homogeneous
mutation pattern, in some tumors there appeared to be a subclone o f cells that
exhibited a different mutational picture. In two cases, a mutation was found in the
deep tissue o f the tumor, while there were no mutations found in the rest of the tumor.
These subclones were also characterized by different DNA aneuploidy patterns.
However, in the case of lymph node metastasis, the mutation pattern o f the nodes
matched that of the tumor.
Studying 40 early colonic carcinomas, Ohmura and Haitori (38) obtained
similar results. While most cancers developed monoclonally, they found one case
that demonstrated a mutation in the carcinoma that was not found in the adenoma.
They also found a case that demonstrated one mutation in the adenoma and an
additional mutation in the carcinoma. The authors suggested that these could have
arisen from the “collision” of two clones. However, it may also be possible that the
additional mutations occurred during tumor progression.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER m

PURPOSE OF STUDY

At the time of publication o f their recommendations for the use o f prognostic
markers in 1995, the College of American Pathologists suggested that K-ras would be
the first genetic marker to be designated as a Category H prognostic marker (9).
However, with conflicting views concerning the meaning of specific K-ras mutations,
it would be difficult to use mutation information to influence treatment of colorectal
cancer.

It was the purpose o f this study to further characterize the relationship

between specific mutations and outcome in this disease.
Even if no relationship exists between the specific mutations found in tumors
and the length of disease-free survival in colorectal cancer, it may be possible to use
information concerning the mutational status of tumors, as a ‘molecular finger print’
to detect micrometastasis. Therefore, a further purpose was to determine whether or
not micrometastasis, identified by the mutational status of lymph nodes as compared
to associated tumors, was associated with the length of disease-free survival.
In order to accomplish the above, the author utilized paraffin-embedded
archival material for which the necessary clinical and histopathological data was
available. A variety of methods for extraction of DNA from this material and for Kras mutation analysis were analyzed in order to develop methods that utilized this
material optimally.
9
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CHAPTER IV

ISOLATION OF DNA FROM ARCHIVAL MATERIAL

Background

Much o f the early work to characterize the relationship between K-ras and
colorectal cancer (CRC) was done with very small sample numbers of fresh tissue or
cell lines. It is recognized that more extensive studies with long-term follow-up are
needed to fully characterize this relationship.

This would take many years to

complete using fresh tissues. Consequently, it is very appealing to use archival tissue
for which recurrence and survival data has been collected.
Many groups have attempted to use archival material, and there has been a
virtual explosion o f such work in the past five years. However, extraction o f DNA
suitable for analysis from these formalin-fixed, paraffin-embedded tissues has proven
to be problematic. This can be evidenced by the variety of methods developed to
improve upon previous methods, some of which work in as little as 20-30% of
samples. A description of the available methods follows.

Methods Utilizing Microdissection for Enrichment

Some techniques rely upon microdissection o f paraffin sections.

The

advantage o f using microdissection is that the sample is enriched for the cells of
10
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interest, i.e., tumor cells.

This eliminates “background noise” from surrounding

tissues, and thus increases the sensitivity of mutation detection methods.

Methods With Digestion and Purification

The earliest methods used for extraction of DNA from paraffin-embedded
tissues followed the basic steps reported by Blin and Stafford (39) for the extraction
o f DNA from eukaryotic cells. These steps include cell lysis, protein digestion with
proteinase K, protein precipitation, and purification of the DNA-containing
supernatant with phenol and chloroform.

This method was later modified by

Sambrook, Fritsch, and Maniatis (40), and has become widely used for the extraction
o f DNA from mammalian cells.
Goelz, Hamilton, and Vogelstein (41) published a method in 1985 that
included the steps o f Blin and Stafford (39). Prior to the extraction, sections 6 p. thick
were cut from paraffin blocks and stained with hematoxylin and eosin for
histopathologic exam. These were used to guide the removal of at least 50 mg of
tumor tissue from the intact paraffin block. Care was taken to trim away as much
paraffin as possible, and the tissue was finely minced before proceeding. In their
adaptation, lysis and digestion were performed twice—once for 24 hours and a
second time for 40 hours, with vigorous vortexing prior to each incubation.
Following digestion, the tissue was vortexed again, and forced through an 18-gauge
needle three times. Purification o f DNA was performed three times with phenolchloroform (3 parts phenol, 4 parts chloroform, and 2 parts Tris-EDTA pH 9.0).
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Goelz et al. (41) used their method to extract DNA from fresh frozen, fixed,
fixed and embedded, and archival tissues. They examined the condition of the DNA
following extraction and found that fixation in formaldehyde did not significantly
affect results. However, the amount of DNA extracted from freshly embedded tissues
was approximately half that of the tissues that were only fixed.

Further, DNA

extracted from archival tissue (embedded in paraffin and accumulated over a fiveyear period) was highly degraded. The size of recovered DNA ranged from 100 base
pairs (bp) to 10,000 bp, with most of the DNA being between 100 and 1500 bp in
length. They also determined that approximately 25% of the 30 samples tested were
not suitable for use in blotting or cloning applications.
Others have since used the method o f Goelz et al. (41) with slight variations.
The most common variation is the use o f microdissected tissue removed directly from
the stained slide (42,43) or use of a stained slide to guide removal o f tissue from an
unstained slide (44,45). Still others have added a deparaffinization step, which uses
xylene to remove the paraffin prior to digestion (46,47). These methods also decrease
the digestion step to 24 hours (46) or to overnight (47-49). One group decreased
digestion to overnight without deparaffinization (50).

Methods With Digestion and Without Purification

A further variation is to eliminate the DNA purification with phenolchloroform following digestion. The digest is centrifuged, and the supernatant used
in amplification protocols. This approach has been used to extract DNA from cells
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scraped from either stained (51) or unstained slides (52-56). The method may also be
preceded by deparaffinization with xylene (52-54).
Similar methods have been used, but with variations in microdissection
techniques. One such variation is the use of ultraviolet (UV) light to destroy DNA
from normal-appearing cells, thus isolating only DNA from tumor cells (57-59).
With this technique a black marker is used to identify the location o f tumor cells on
the slide, and protect them from UV irradiation. After marking, the slide is placed
marked-side down on a UV transilluminator for 2-4 hours. The tissue is then scraped
from the slide into a microcentrifuge tube.
Being concerned by the possibility that marking in the above manner may not
fully protect the tumor cells from irradiation, Turbett et a l (60) developed a
technique to select cells of interest without scraping or irradiation.

They used a

nontoxic starch-based craft glue to identify the cells of interest. Xylene cyanole was
added to the glue to aid in visualization.

Areas of tumor cells were selected by

covering them with the glue using a fine needle. Once the glue dried, the selections
were lifted from the slide using forceps, and placed into lysis/digestion buffer. The
authors found this method to be useful in the selection of areas varying greatly in size
with ease.
Following extraction by the above methods, a portion of the digest was added
to an amplification mix prior to cycling.

A variation on this technique adds the

amplification components directly to the full volume of digested sample (61). This
eliminates further manipulations and minimizes opportunities for contamination.
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14
Methods Using DNA Exposure

Still other methods eliminate both the DNA purification with phenolchloroform and the protein digestion steps. These produce a crude extract that is used
directly in amplification protocols. The idea behind this type o f method is not only
the elimination o f time-intensive steps, but more importantly, the reduction o f sample
lost during multiple processing steps.
Finkelstein et al. (62) used a method in which tumor cells were selected by
microdissection from deparaffinized slides and placed directly into an amplification
mixture. They found efficiency of amplification of DNA extracted in this manner to
be significantly reduced, and noted the presence of non-specific amplification
products. Others have used similar techniques, but fail to comment on the level of
success (63).

Crude DNA exposure techniques have also been used without

deparaffinizing the sample prior to microdissection (64-66)

Methods Without Enrichment

With some methods, DNA is extracted directly from intact paraffin sections
without enrichment for tumor cells. These methods may or may not use xylene to
wash away paraffin prior to extraction.

Methods With Digestion and Purification

These methods are similar to those of Goelz et al. (41), but with the
elimination of microdissection.

All groups who report using this method
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deparaffinize with xylene prior to DNA extraction (13,44,67-71).

After

deparaffinization, the length o f digestion varies from overnight up to 48 hours.
Although the level o f success in obtaining amplifiable DNA is rarely reported, one
group reported obtaining DNA suitable for study in 45.3% (68/150) o f the cases
tested (71).

Methods With Digestion and Without Purification

As with techniques in which microdissection is used, some groups eliminate
the phenol-chloroform steps o f the protocol. This method is used with (13,33,72-77)
or without deparaffinization (78,79) and with variations in length of digestion.
Wang et al. (80) evaluated three different methods for extraction from
paraffin-embedded tissues, and found this method to be the best. They reported that
neither the addition o f deparaffinization with xylene nor purification with phenolchloroform improved results.

Methods Using DNA Exposure

There are several variations of DNA exposure without microdissection. With
the first method, paraffin sections are deparaffinized with xylene and mixing, the
xylene is removed with ethanol washes, the sample is desiccated, and then boiled in
either TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA pH 8.0) (78) or water (81-83) to
release the DNA. A portion o f this sample is added to the amplification mix before
cycling. In another method, the step involving boiling in TE or water is eliminated.
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Instead, the amplification mix is added directly to the desiccated sample, and the mix
is subjected to boiling for 10 minutes prior to amplification (84,85).
Two groups have worked to improve upon this method by adding Triton X to
the amplification mix to stabilize Taq DNA polymerase and aid in DNA release
(86,87). With this method, a section from the paraffin block is placed directly into a
reaction tube with the amplification mix, and heated at 95°C for 20 minutes prior to
amplification. Although this reduces sample handling, it requires a large reaction
volume in order to submerge the section.

Materials and Methods

PCR Design and Optimization

In order to evaluate methods for the extraction of DNA from paraffinembedded archival tissue, the author first designed an amplification experiment. The
design was then used to determine whether or not DNA extracted using a particular
method would be suitable for mutation analysis.

Primer Design

After evaluating a number of either commercially available (Oncogene Point
Primer Set, catalogue number APS07) or published primer sets (44,81,88,89) with
variable results, the author designed primers using National Biosciences, Inc.’s
OLIGO™ software package. A pair of primers was designed, which would produce a
275 base pair PCR product containing codons 12 and 13 of exon one. The primers,
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which had essentially the same Tm and lacked significant hairpin or dimer formation,
were manufactured commercially by National Biosciences, Inc. (NBI).

These

primers could also be paired with the Oncogene primers to produce 205 or 178 base
pair products.

The Oncogene primers amplify a 107 base pair region.

Primer

sequences were:
NBIa: 5’ gtactggtggagtatttg 3’

NBIb: 5’ cagagaaacctttatctg3’

OncA: 5’ gactgaatataaacttgtgg 3’

OncB: 5’ ctattgttggatcatattcg 3’

PCR Optimization

In order to produce the most product with the highest level of specificity (i.e.,
no nonspecific product), the PCR conditions must be optimal.

The annealing

temperature was first determined, and then the concentration of four reaction
components (MgCb, primers, dNTPs, and target DNA) were optimized at that
temperature.
Annealing temperature is critical to the achievement of optimal PCR results.
Poor yield of product will result from an annealing temperature that is too high, while
a low annealing temperature will result in non-specific PCR products (90).

The

annealing temperature for this experiment was determined using National
Biosciences, Inc.’s OLIGO™ software package.
Optimizing amplification conditions can be a time-consuming proposition.
For example, if one were to test four different reaction components at three different
concentrations, it would take 81 reactions to find the optimal combination! Cobb et
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al. (91) reported using Taguchi’s engineering method to optimize PCR. The method
was developed by Taguchi to optimize industrial design processes using a minimal
number o f experiments.
The Taguchi method utilizes the properties of an orthogonal array to
determine the effect o f one component on another. Using Cobb’s (91) adaptation of
this method, four PCR components (MgCfe, primers, dNTPs, and target DNA) at
three concentrations were evaluated in nine reactions. Table 2 shows the components
and concentrations used to determine the optimal conditions for initial amplifications.
The concentrations to be used were determined by first estimating level B for

Table 2
Components and Concentrations Applied to Taguchi Array

Concentrations

Component

A

B

c

Units

I

Primers

0.4

0.8

1.8

(iM

II

Template

0.2

1.0

2.0

Hg/100|il

m

MgCl2

0.5

1.5

4.0

mM

IV

dNTP Mix

60

100

200

pM
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each component. This was done by a review of reported concentrations used in
amplification o f this gene, and the manufacturer’s recommendations (Perkin Elmer
GeneAmp Core Reagents Kit). Levels A and C were then determined by using the
most extreme conditions reported for this gene.
The PCR components were distributed into nine tubes, following the Taguchi
array shown in Table 3. Note that, between any two columns, all combinations o f
concentrations (designated by A, B, and C) have the same frequency.

Table 3
3 X 4 Taguchi Array

Component

Reaction #

I

n

III

IV

1

A

A

A

A

2

A

B

B

B

3

A

C

C

C

4

B

A

B

C

5

B

B

C

A

6

B

C

A

B

7

C

A

C

B

8

C

B

A

C

9

C

C

B

A
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DNA for this optimization procedure was obtained from fresh tumor cells
derived from the pleural fluid of a patient with lung cancer, which was donated by the
West Michigan Flow Cytometry Laboratory in Grand Rapids, Michigan. Genomic
DNA was extracted from this sample using the Puregene DNA Isolation Kit,
manufactured by Gentra Systems, according to instructions provided with the kit.
Briefly, the cells were washed with Cell Suspension Solution and pelleted by
centrifuging at 1000 X g for 15 minutes in a refrigerated centrifuge. The pellet was
resuspended in Cell Lysis Solution and proteinase K was added to a concentration of
100 Mg/ml. The mixture was incubated for two hours at 55°C. The protein was
precipitated with the Protein Precipitating solution provided, and pelleted by
centrifuging at 16,000 X g for 3 minutes. DNA was precipitated from the supernatant
using isopropanol, and pelleted by centrifuging at 16,000 X g for 5 minutes. After
washing the pellet once with 70% ethanol, and allowing it to dry at room temperature,
the DNA was resuspended in DNA Hydration Solution by heating at 65°C until
dissolved, and stored at -70°C until use.
Amplification of a 275 bp region of exon 1 (NBI primers described above)
was performed in a 100 pi total reaction volume using the Perkin Elmer Core PCR kit
and run on a Perkin Elmer 480 thermocycler (additional reaction conditions: 10 mM
Tris-HCl pH 8.3, 50 mM KC1, and 2.5 Units Taq polymerase). The tubes were gently
mixed and overlaid with mineral oil prior to amplification.

The amplification

program consisted of an initial denaturing step for 5 minutes at 95°C, 30 cycles of
PCR, and a final extension of 10 minutes at 72°C. Each PCR cycle consisted of 1
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minute at 95°C, 2 minutes at 52°C, and 1 minute at 72°C.
Following amplification, the PCR products were electrophoresed at 80 Volts
for 40 minutes in a 2% GTG agarose gel (Seakem) containing ethidium bromide
(Figure 2). The gel was photographed with a Polaroid camera using ultraviolet epi-

s

Figure 2.

11

\ i

PCR Optimization Gel.

illumination, and the yield of PCR product for each reaction was visually scored. The
quadratic loss function was applied to determine signal-to-noise ratios (SNL) for each
concentration:
n
SNL = -10 log

i I

1

n
y2
- /= 1 Where: n = number of levels, y = yield, and / = index.
For any component, the concentration with the highest signal-to-noise ratio
was designated as the optimal o f the concentrations tested.

This calculation was
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repeated for each o f the components tested. The concentrations determined to be
optimal for the four components were combined for future amplifications (4.0 mM
MgCfe, 200 pM each dNTP, 0.8 pM each primer, and 1.0 pg target DNA). Note that
this combination was not represented in the nine reactions performed here. These
conditions were subsequently used to evaluate extraction methods.
Anticipating that this method might be used multiple times, this author
developed a simple computer program for doing this calculation and reporting the
optimal level for each component. The program, which may be found in Appendix
A, runs in Microsoft Q Basic. This modification of Taguchi’s method was used to
optimize all amplification reactions used in this work.

Methods for DNA Extraction From Archival Material

A variety o f extraction methods were used by this author to determine the
optimal approach for the extraction of amplifiable DNA from archival tissue. The
success of each method was analyzed by amplifying a 275 bp region o f the K-ras
gene from each DNA sample using the PCR program described above with conditions
determined through the described optimization (final conditions: 10 mM Tris-HCl pH
8.3, 50 mM KC1, 4.0 mM MgCfe, 200 pM each dNTP, 0.8 pM each NBI primer, 1.0
pg target DNA, and 2.5 Units Taq polymerase in a total reaction volume o f 100 pi).
A summary o f the methods used is shown in Table 4. These methods are listed in
order o f complexity, not in the order o f trials. Unless indicated, the exact conditions
for each step followed a standard protocol, described below.
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Table 4
Methods Used for the Extraction of DNA From Archival Tissues

Method #

Reference #/
Or Kit Used

Sections Used

Xylene

Cell Lysis/
Digestion

DNA Extraction

1

(40)

5-10 x 10 |i

1-3 washes

8-72 hours 55°C

Organic

1/10

10

2

(92)

5-10 x 10 p

1-3 washes

2 hours 55°C a

Organica

0/30

0

3

(33,52)

5-10 x 10 p

1-3 washes

14-16 hours 55°C

None

1/5

20

4

Puregene

5 x 10 p

1 wash

Per kit

Per kit

1/3

33

5

Puregene

5 x 10 p

1 wash

Per kit

Protein
Precipitated b

1/3

33

6

Puregene

5 x 10 p

1 wash

Per kit

None

0/3

0

7

Puregene

5 x 10 p

1 wash

None

None

0/3

0

8

(60)

1 x 10 p

None

16-24 hours 55°C

None

4/13

31

AN1

A%2

to

u>
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Table 4 -Continued

Method #

Reference #/
Or Kit Used

Sections Used

Xylene

Cell Lysis/
Digestion

DNA Extraction

AN1

A%2

9

(93)

1 x 10 )i

None

20 minutes in ROSEc
with mixing at 90°C

None

13/62

21

10

GeneReleaser

l x l O^ i

None

1-2 minutes in reagent
microwaved on high

None

0/5

0

11

(94)

1x10^

None

1-2 minutes in TE
microwaved on high

None

0/10

0

12

(65)

1 x 10 n

None

Boiled in 100 |il TE
For 10 minutes

None

0/10

0

13

(81)

1 x 10 | l i

2 washes

Boiled in 100 |il sterile
water for 10 minutes

None

2/3

67

14

None

1 -5 x 10 n

None

Boiled in water for 15
minutes, 100 |il/ section

None

59/71

83

15

None

1 -5 x 10 (i

None

Heated in Thermomixer
15 minutes at 95°C

None

5/10

50

to

A
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Table 4 -Continued

Method #

Reference #/
Or Kit Used

Sections Used

Xylene

Cell Lysis/
Digestion

DNA Extraction

AN1

A%2

16

None

1 -5 x 10 p

None

Heated in Thermomixer
30 minutes at 95°C

None

3/10

30

17

(55)

1 x 10 p

None

None d

None

0/5

0

Legend:

1 = AN represents the number of successful amplifications/number of attempts
2 = A% represents the % of successful amplifications
a = Digestion and extraction performed in a Serum Separation Tube (SST) to reduce sample transfer
b = Digest used directly for PCR after protein is precipitated
c = ROSE (Rapid One-Step Extraction) buffer, 10 mM Tris-HCl pH8.0, 312.5 mM EDTA pH 8.0, 1% sodium
lauryl sarkosyl, and 1% polyvinylpolypyrrolidone (PVPP)
d = Paraffin section placed in amplification mix and heated at 95°C for 10 minutes prior to amplification

to
L /l

Deparaffinization washes were performed with 1.0 ml o f xylene, incubated for
5 minutes, and aspirated following centrifugation at 16,000 X g for 5-10 minutes.
Following the number of washes indicated, the xylene was washed away with 0.5 ml
o f ethanol, and the pellet dried at 37°C.
If a kit was used, 600 pi of the lysis solution provided with the kit was added
to the cell pellet, along with proteinase K to a concentration o f 100 pg/ml, and the
sample was incubated as shown. If a kit was not used, cell lysis and digestion was
performed in 1 ml of digestion/lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM
EDTA, pH 8.0, 100 mM NaCl, 3.0% SDS, 100 jig/ml proteinase K), and the sample
was incubated as shown.
For organic methods, three extractions were performed with phenolchloroform-isoamyl alcohol (25:24:1).

Each extraction was performed in 1ml,

centrifuged for 5 minutes at 16,000 X g, with the aqueous layer used for the next step.
Following the third extraction, the DNA was precipitated from the aqueous layer with
1.0 ml o f ice cold absolute ethanol, pelleted by centrifuging at 16,000 X g for 15
minutes, rinsed once in 1 ml of 70% ethanol, dried in a centrifugal vacuum
concentrator, and resuspended in TE.
For nonorganic extractions, protein was precipitated from the digest using a
protein precipitating solution (provided in the kit), and centrifuged for two minutes at
16.000 X g. DNA was precipitated from the supernatant as described for organic
methods.
Initially, methods were tried repeatedly (methods 1, 2, 8, and 9), then trials
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were limited to 10 (methods 1, 11, or 12). In later trials, only methods that worked
for the first 3-5 samples were further analyzed. Methods 13 and 14 were evaluated
simultaneously. Although method 13 was successful in 2 o f the first 3 reactions,
method 14 produced amplifiable DNA in all initial tests.

Since method 14 was

initially successful and eliminated the use of xylene, it was further evaluated.
Using method number 14, which consisted of boiling one 10 micron thick
section in 100 pi of sterile water for 15 minutes, experiments were designed to
determine whether the method could be improved. Parameters investigated were: (a)
the thickness of the sections, (b) the number of sections per volume of water, (c) the
method o f heating, (d) effect o f mixing during heating, (e) the effect of centrifuging
following heating, (f) the effect o f cooling following heating, (g) the effect of storage,
and (h) the effect of using a set volume of extract in amplification experiments.
For evaluation of section thickness, sections were cut that were 5 microns, 10
microns, and 20 microns thick and boiled in 100 pi sterile water. It was determined
that amplification was optimal with sections 10 microns thick. The author theorized
that 5 microns did not provide enough tissue, and that excess paraffin may have
interfered when using sections 20 microns thick.
The effect of the number of sections used was tested by using 1, 5, or 10
sections (10 microns thick) in 100-500 pi of sterile water. Ten sections were found to
be difficult to work with. One section in 100 pi of sterile water produced the optimal
PCR product, and was also easiest to handle.
Two methods of heating were evaluated: (1) boiling and (2) heating at 95°C
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in an Eppendorf Thermomixer, with no difference detected. The effect o f mixing
while heating was evaluated in the Thermomixer, set to the lowest speed. It was
theorized that mixing may aid in disbursement of paraffin and cells, but no difference
was found.
Since condensation formed on the inside of the tubes, the author thought that
centrifugation should be performed to avoid aerosols, which may result in carryover.
Samples were briefly centrifuged (10-15 seconds at 16,000 X g) to collect the
samples into the bottoms of the tubes. Since no difference in amplification was found
by adding this step, and it was a good preventative measure, it was added to the
protocol.
Following heating, samples were cooled at 4°C or on ice for 5-15 minutes
before testing. This improved results slightly, with no effect after 10 minutes. There
was no difference observed between the two temperatures, except that the paraffin
hardened more on ice. Since the paraffin formed a barrier on top o f the sample, this
made removal of the sample more difficult. Therefore, cooling for 10 minutes at 4°C
was used.
The effect of storage was evaluated at room temperature, 4°C, -20°C, and
-70°C.

At room temperature, the samples were unamplifiable after a few hours.

When stored at 4°C, the samples amplified after 2-3 days, while this was extended to
approximately 2 weeks when stored at -20°C. Long-term storage was only possible
when the samples were placed at -70°C.
Although the optimal concentration for target DNA was determined by the
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Taguchi method to be 1 |ig/100 |xl using fresh tissues, there seemed to be some
variation in results from paraffin block to paraffin block, which appeared to be
associated with the volume o f extract used in amplification. Noting that some other
authors used a set volume of extract rather than a set amount o f DNA in amplification
reactions, the author decided to evaluate this approach.
Experiments were designed to evaluate the addition of 10, 25, or 40 (il of
crude extract to a 100 pi total reaction volume. Amplification was most consistent
using 25 pi of DNA extract, regardless of DNA concentration. This may have been
caused by the presence o f PCR inhibitors in the paraffin blocks, which could have
been released during extraction. This theory was tested by adding varying amounts of
the paraffin to an extract of fresh cells and heating, and was found to be correct—PCR
was inhibited by this addition. This would also explain why using thicker or a greater
number of sections had a negative effect in previous experiments.
While performing these tests, it was noted that processing the samples in large
batches yielded poor results. It was subsequently determined that small batches of 8
to 10 samples worked best, and extractions were performed in this manner in all
subsequent experiments.

Results

As a result of these tests, a standard method was developed for the extraction
o f DNA from paraffin blocks. A single 10 micron-thick section was removed from
each paraffin block using a disposable microtome blade, and placed into a sterile
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microcentrifuge tube. All instruments were thoroughly cleaned with chlorine bleach
followed by ethanol, and gloves were changed between each sample to prevent cross
contamination.

For extraction, no more than 8-10 samples were processed

simultaneously. Sterile, ultrafiltered, deionized water was added to each tube in the
volume o f 100 |il. The tubes were sealed and heated at 95°C for 15 minutes, and
briefly centrifuged to collect the sample into the bottom o f the tubes, followed by
cooling for 10 minutes at 4°C. The layer of paraffin was pierced with a pipette tip,
and the supernatant was transferred to a second sterile tube and stored at -70°C until
use. Twenty-five |ri o f each extract was used in a 100 |il amplification reaction. This
method will be referred to as ‘modified method 14’.

Discussion

The DNA from paraffin-embedded archival material is generally of poor
quality (41) due to damage during the formalin fixation process (81). This makes
isolation of DNA suitable for analysis a challenge. A variety of methods for the
extraction o f DNA from archival material were reviewed by this author. Many of the
methods enriched for tumor cells by using microdissection.

This required that

multiple slides be prepared from each tissue block to be tested. The current project
examined tumors from approximately 100 patients and an additional five to ten
blocks of lymph nodes from 20 patients. This would require that approximately
2000-3000 slides be prepared, which was not within the scope of the project.
Furthermore, lymph node micrometastases in Dukes’ B2 patients could not be
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visualized with histopathological analysis, making enrichment for tumor cells in
lymph nodes impossible with this method.

Therefore, an approach that did not

require microdissection was sought.
There was a risk that the small amounts o f DNA that would be suitable for
amplification may have been lost during the extraction process. This risk could be
minimized with the elimination of steps from the extraction method. Several groups
have tried this approach. After evaluating the existing methods, this author theorized
that paraffin might be satisfactorily removed while performing heat lysis o f the cells,
eliminating the need for deparaffinization with xylene. Since a fairly high volume of
extract was transferred to the amplification reaction, the composition o f the lysis
solution was critical. Ions and chemicals contained in the solution could affect the
processivity o f the polymerase. Therefore, water was used as the lysis solution, to
eliminate the transfer of unwanted additional components to the amplification mix.
Even though this method yielded a crude DNA extract, it proved to be very
useful for this project.

Additionally, since there were few manipulations of the

samples, the risk o f cross-contamination events was minimized.

Conclusions

O f the methods analyzed, the simplest proved to be the most successful and
reliable (modified method 14, page 29). Amplifiable DNA was obtained from a
single paraffin section by heating in sterile water. Manipulations of the sample were
minimized, reducing the possibility of cross-contamination or loss of valuable DNA
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CHAPTER V

MUTATION DETECTION AND ANALYSIS

Background

The incidence of mutations, as well as the exact nature of mutations in respect
to location and type, varies considerably depending upon the selection of samples and
the analytical method used. There are a variety of methods used to detect mutations
in the K-ras gene. These methods vary in sensitivity and specificity. This section
will give an overview of these methods.

DNA Sequencing

PCR followed by direct sequencing has been used to detect K-ras mutations in
lesions o f the mouse liver (81), as well as human tumors located in the pancreas (44),
esophagus (45), and colon (62,63,71,73,95).

Although sequencing is generally

regarded as the ‘gold standard’ when it comes to identification of specific mutations,
it is only able to detect mutant sequences that represent approximately 25% or more
of the total sample (62,96). For this reason, microdissection is generally used to
enrich for cells of interest prior to DNA extraction and PCR amplification.

32
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Single-Strand Conformation Polymorphism

PCR followed by single-strand conformation polymorphism (SSCP) is a
mutation detection method, which relies upon the folding of single-stranded DNA,
and assumes that a point mutation will result in a conformation change that will alter
mobility during electrophoresis.

Reliability of SSCP is highly dependent upon

electrophoretic conditions, which may also affect mobility. Since the electrophoresis
may continue for up to 18 hours (72), a system for controlling the temperature o f the
gel is employed (35).
This method has been used to detect mutations in gastric tumors (97),
pancreatic tumors (98), lung tumors (88), bone lesions (80), and breast tumors (88),
as well as in tumors of the colon and rectum (36,52,72) SSCP is reported to detect as
few as 10% mutant sequences in a background of normal DNA (36).
SSCP is limited to the detection of mutations, and is unable to identify the
specific type or location of point mutations, even when the mutation is known prior to
analysis (52). Therefore, positive results are often confirmed with sequencing in
order to identify the specific mutation present (36,52,72,88).

However, without

enrichment prior to sequencing, 23% of mutations detected with SSCP are not
confirmed (72). Therefore, it is advisable to use microdissection to enrich for tumor
cells.

Dot Blot Analysis

Point mutations can alter the ability o f DNA probes to bind to specific DNA
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sequences. Dct blot analysis takes advantage o f this specificity using oligonucleotide
probes under stringent conditions. DNA is blotted onto a membrane, such as nylon,
and then hybridized to mutation-specific oligonucleotide probes.
Dot blot analysis has been used to identify K-ras mutations in tumors of the
ovary (96), lung (58,75) pancreas (66), and colon (13,33,35,38,83,99,100). Results
vary according to the probes used, hybridization conditions, and stringency of
washes. Under proper conditions, only perfectly matched probes should hybridize to
the DNA target sequence.

When this is achieved, single-base discrimination is

possible (100). However, a separate probe must be made to detect each possible
mutation. This would require 16 different probes for each codon, and would still not
allow the detection o f concurrent mutations in both codon 12 and 13 (99).

Mutant-Enriched Restriction Fragment Length Polymorphism

A variation of the restriction fragment length polymorphism (RFLP) has been
designed to create artificial restriction sites in an area of interest.

This method,

designated here as mutant-enriched RFLP (ME-RFLP), has also been referred to as
mismatched-primer mediated PCR-RFLP (101), more simply as mismatched PCRRFLP (102), primer-mediated RFLP (103), or as amplification-created restriction
sites (ACRS) (53).
Applied to mutation detection in K-ras, the simplest of these methods uses a
mismatched 3’ PCR primer to create a Bst NI restriction site that extends into codon
12 (34,76,77,104) (Figure 3). Following PCR amplification, products are digested
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with Bst NI.

Only DNA containing the wild-type sequence in codon 12 is

successfully digested, as any mutation in the first two positions o f codon 12 would
eliminate the restriction site. The digest is then analyzed using polyacrylamide gel
electrophoresis (PAGE) (7,76) or high-resolution agarose electrophoresis (105).
Following electrophoresis, the gel is stained with ethidium bromide for visualization
(106).

cctgg

Bst NI recognition sequence

at aaa ctt gtg gta gtt gga cct

Mismatched primer

5’.......at aaa ctt gtg gta gtt gga get ggt ggc gta . .... 3 ’
11 12 13

K-ras wild-type sequence
Codon number

f-

Figure 3.

Downstream Primer

Primer Design for ME-RFLP.

The most common variation of ME-RFLP is the two-stage, or mutantenriched method (105). With this method, following PCR and restriction digest, a
second round of PCR is performed (70). This may be followed with a second digest
(42,43,79,103) One group has added a third-stage of PCR and digestion (107).
Another variation is separate testing for mutations at codon 13 with the
creation of a different restriction site, most commonly Hph I (108), which only
detects GGC ■) GAC mutations (109). Creation of other restriction sites at codons
12, 13, and 61 have also been used (54,106,107,101,110). The length of digestion
varies considerably, with digestion for as long as 16 hours (105).
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ME-RPLP has been used to screen for mutations in tumors of the lung
(54,102), stomach or esophagus (56,108), pancreas (76,79), and endometrium (53), as
well as in the colon and rectum (42,43,51,57,70,101,107-112). While the method
identifies the presence of a point mutation in position 1 or 2 of codon 12, it does not
identify the specific type o f mutation.

Allele-Specific Polymerase Chain Reaction

Allele-specific polymerase chain reaction (AS-PCR) is a variation of PCR,
which relies upon a requirement of Taq polymerase that there be a perfect match
between the 3’ end of the DNA primer and its target sequence (89).

Since Taq

polymerase lacks proof-reading ability, a mismatch at the extreme 3’ end of the
primer will prevent the polymerase from extending the DNA strand (67,79). This
method can be used both to detect and to identify specific mutations, eliminating the
need for sequencing.

It has also been referred to as mutant allele specific

amplification (MASA) (113).
AS-PCR is useful for detecting and characterizing mutations in genes (such as
K-ras) that have specific sites where mutations have been identified. By positioning
the 3’ end of the primer directly over the nucleotide in question, and varying the 3’
nucleotide of the primer, the nucleotide on the target DNA can be identified (89)
(Figure 4).

Following amplification, products are subjected to agarose gel

electrophoresis and visualized with ethidium bromide staining.
AS-PCR in its simplest form has been used to detect a single, specific
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mutation found in the blood cells of patients with acute myelogenous leukemia (1 14).
With this application, a single mutant-specific primer was used to screen for
malignant cells.

tg gta gtt gga get n

Mutation-specific primer

5’.......at aaa ctt gtg gta gtt gga gctggt ggc g ta ....... 3’
11 12 13

K-ras wild-type sequence
Codon number

<r

Figure 4.

Downstream Primer

AS-PCR Primer Design for Position 1 o f Codon 12.

When applying this method to colon cancer, most groups have screened for all
possible mutations o f codon 12. Some groups have added screening for the most
common glycine to aspartic acid mutation o f codon 13 (115), while others have also
screened for serine or arginine at this site (65,78). A more aggressive approach has
been used to screen for all possible mutation at all three of the above mentioned
positions, requiring twelve mutant-specific primers (113) (Figure 5).
A further variation of this method is to employ multiplex PCR to screen for all
mutations o f a particular position at the same time, in order to reduce the number of
amplification reactions required (67,78,113). With this approach, only the position of
the mutation can be determined in the original screening reactions. Additional tests
must be run to determine the exact type of mutation in a positive screen.
In studying mutations in liver cancer, Stork et al. (89) have applied this
method to the detection of K-ras mutations in the first two positions of codon 12
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With their approach, position one is screened using a mutant-specific primer in the
sense direction, while a mutant-specific primer in the antisense direction is applied to
position two (Figure 6). When designed in this fashion, mutations in position one do

5’

tg gta gtt gga get ggt gw ->

13b mutation-specific primer

tg gta gtt gga get gn ->

12b mutation-specific primer

tg gta gtt gga get n ->

12a mutation-specific primer

... ctt gtg gta gtt gga get ggt ggc gta ggc aag . .... 3 ’
12 13

K-ras wild-type sequence
Codon number
Downstream Primer

Figure 5.

AS-PCR Primer Design for Codon 12 and Position 1 of Codon 13.

tg gta gtt gga get n ->
5’

... ctt gtg gta gtt gga get ggt ggc gta ggc aag ..
11 12 13

12a mutation-specific primer
3’

K-ras wild-type sequence
Codon number

<r

Downstream Primer

->
S’

Upstream Primer
... gta gtt gga get ggt ggc gta ggc aag agt gcc..
11 12 13
4- «a ccg cat ccg ttc tea

Figure 6.

3’

K-ras wild-type sequence
Codon number
12b mutation-specific primer

Opposing AS-PCR Primer Design for Codon 12.
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not interfere with detection o f mutations in position two.

However, codon 13

mutations can not be analyzed with this method.

Allele-Specific Ligation Assay

A variation of the ligation assay, the allele-specific ligation assay combines
the most attractive features o f ligation and AS-PCR.

In the ligation assay, two

labeled probes are designed to anneal side-by-side on the target DNA. Following
annealing, a ligation reaction joins the two probes into a single, longer sequence. If
both probes anneal in the proper orientation, ligation will occur and the larger ligation
product will be seen when analyzed electrophoretically,

otherwise bands

corresponding to the two smaller probes will be seen.
For the allele-specific ligation assay, the mutant-specific probes are designed
similarly to the mutant specific primers of AS-PCR. The second, or common, probe
is designed just 3’ of the mutant-specific probe (116). A third probe (the blocking
probe) overlaps the site of ligation (117) (Figure 7). The blocking probe is perfectly
matched to the wild-type sequence, and competes with the mutant-specific probe.
Since oligonucleotides with a single base mismatched bind weaker than perfectly
matched oligonucleotides (84), this decreases the opportunity for non-specific
ligation. This assay has been used to detect K-ras mutations in colorectal cancer
(117,118). The method does not detect multiple mutations unless probes are designed
specifically for their detection (116).
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40
Blocking Probe
Specific Probe—gtt gga get
lommon Probe
Product
3’
K
5’
ctt gtg gta gtt gga get Agt ggc gta ggc
K-ras
mutant sequence
11 12 13
Codon number
Successful Ligation—Blocking Probe Displaced
Specific Probe- |gtt gga get

5’

|gt ggc gta g] -Com mon Probe

gta gtt gga get ggt ggc gta ggc aag agt gcc
11 12 13

3’

Blocking Probe
K-ras wild-type sequence
Codon number

_______________Ligation Blocked—Ligation Probes Displaced_______________
Legend:

/»= a, t, or c

ligase

Figure 7.

Allele-Specific Ligation Assay for Position 1 of Codon 12.

RNAse Mismatch Cleavage Assay

When RNA extraction is possible, the RNAse mismatch cleavage assay may
be used for mutation detection. Specific, labeled RNA probes are annealed to the
region of interest. If mismatches are present, single-stranded regions are available for
RNAse digestion. The digest products are visualized by denaturing PAGE (119).
This method has been used to detect K-ras mutations in colon cancer (120).

A

variation of this method employs DNA probes, and relies upon the formation of
DNA:RNA hybrids prior to RNAse digestion (82). The location or type of mutation
can not be identified without further testing.
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Immunohistochemical Staining

This author found one report o f immunohistochemical staining applied to the
detection of mutations in the K-ras gene (121). The method used anti-ras (rap 5)
antibodies to detect the presence of the K-ras protein on slides prepared from tissue.
The staining was scored by visual analysis o f the distribution o f stained cells, as well
as the intensity o f staining. The authors assumed that activating point mutations
resulted in overexpression of the ras protein, and did not verify the presence of
mutations or determine their types or locations.

Detection Methods and the Reported Incidence of Mutations

The incidence, locations, and types o f mutations reported depends upon the
methods used for detection as well as the selection of the sample population. Table 5
is a summary of the results obtained using the above described methods.

Materials and Methods

O f the above methods, dot blot analysis and AS-PCR were used by this author
to detect mutations in the K-ras gene because of their ability to detect and
characterize mutations without additional testing, reportedly without the use of DNA
enrichment methods. The adaptations employed will be described here.
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Table 5
Incidence of K-ras Mutations in Colorectal Cancer by Type of Detection Method

Reference
Number

Detection
Method

Total Mutations
Number %

% in Codon 12
Asp Val Ala Ser Arg Cys

% in Codon 13
Asp Val Ala Ser Arg Cys

Multiple Mutations
Or Comments

(62)

Sequencing

42/119

35

21

21

14 3

5

10

26

0

0

0

0

0

0

(71)

Sequencing

21/68

31

24

19

19 0

0

0

28

5

0

0

0

0

5% Asp12-Asp13

(63)

Sequencing

25/70

36

(73)

Sequencing

19/37

51

48

26

0

5

0

0

21

0

0

0

0

0

0

(84)

Sequencing

90/247

36

31

20

13

6

1

7

22

0

0

0

0

0

0

(122)

PCR-SSCP

39/43

42

(36)

PCR-SSCP

4/13

31

(72)

PCR-SSCP &
Sequencing

38/73

52

21

26

3

11

0

5

0

0

0

0

3

0

18% Val12+Ala12
5% Vall2+Cys12
8% Val,2+Ala,2+Cys12

(83)

PCR-Slot Blot 48/129

37

25

27

8

13

8

17 2

(38)

PCR-Dot Blot

35

67

11

0

0

0

11

9/26

5% Asp,2+Val12
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Table 5--Continued

Reference
Number

Detection
Method

Total Mutations
Number %

% in Codon 12
Asp Val Ala Ser Arg Cys

% in Codon 13
Asp Val Ala Ser Arg Cys

Multiple Mutations/
Comments

(123)

PCR-Dot Blot

9/24

38

(35)

PCR-Dot Blot

17/65

26

(13)

PCR-Dot Blot

38/92

41

29

16

(33)

PCR-Dot Blot

10/29

34

70

30

(104)

ME-RFLP

25/65

38

Only tested codon 12

(77)

ME-RFLP

6/10

60

Only tested codon 12

(109)

ME-RFLP

98/244

40

Only tested codon 12

(108)

ME-RFLP &
Sequencing

4/15

27

(111)

ME-RFLP &
Sequencing

75/175

43

Only tested codon 12

(51)

ME-RFLP

5/11

45

2-stage-codon 12

79% in codon 12
21% in codon 61

75

0

5

0

13

0

16

0

0

18

3% His61
(16% codon 12 + 13)*

25
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Table 5-Continued

Reference
Number

Detection
Method

Total Mutations
Number %

% in Codon 12
Asp Val Ala Ser Arg Cys

% in Codon 13
Asp Val Ala Ser Arg Cys

Multiple Mutations
Or Comments

(70)

ME-RFLP

26/60

43

2-stage- codon 12

(43)

ME-RFLP

46/92

50

2 stage—codon 12

(42)

ME-RFLP

32/42

76

2-stage—codon 12

(67)

AS-PCR

25/35

71*

+

+

+

+

+

+

+

+

+

Multiplex screen

(113)

AS-PCR

17/43

40

41

6

0

6

0

24

24

0

0

Multiplex screen

(65)

AS-PCR

2/9

22

0

0

0

0

0

50

50

0

0

(118)

Ligation Assay

48/110

44

(116)

Ligation Assay

5/10

50

(120)

RNAse Cleav.

26/66

39

(121)

Immunohisto.

20/55

36

Legend: Blank = Not tested, + = Reported finding, did not report incidence, * = All recurrent, * = Specifics not reported

31% in 12, position 1
69% in 12, position 2

Dot Blot Analysis

Oligonucleotide probes labeled with biotin (for non-isotopic detection) were
purchased from National Biosciences, Inc. (NBI).

The probe sequences, which

analyze all possible single point mutations in K-ras codons 12, 13, and 61, have been
previously described (100).
DNA was extracted from archival tumor samples using the modified method
14 (Chapter n , pages 29-30). A PCR mastermix was prepared and distributed into
thin-walled reaction tubes, 75 pi per tube. Twenty-five pi of DNA were added just
prior to cycling, bringing the final reaction volume to 100 pi (final reaction
conditions: 10 mM Tris-HCl pH 8.3, 50 mM KC1, 0.8 pM each primer, 4.0 mM
MgCh, 200 pM each dNTP, 2.5 Units Taq). The tubes were gently mixed by tapping
and overlaid with mineral oil. Amplification was performed in a Perkin Elmer model
480 thermocycler. The amplification program consisted of an initial denaturing step
for 5 minutes at 95°C, 30 cycles of PCR, and a final extension of 10 minutes at 72°C.
Each PCR cycle consisted of 1 minute at 95°C, 2 minutes at 52°C, and 1 minute at
72°C.
Ten pi of each PCR product were electrophoresed in a 2.0% Seakem GTG
agarose gel for 40 minutes at 80 volts, and visualized with ethidium bromide staining
and UV epi-illumination to verify the presence of PCR product o f the appropriate
size. Seventy-five pi o f each PCR product were purified using Qiagen’s QiaQuik
PCR Purification Kit, following packaged instructions.
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The denatured, purified PCR product was vacuum blotted onto a nylon
membrane using a BioRad dot blot apparatus. The blot was dried for 30 minutes at
80°C, and stored in a sealed container between two sheets of filter paper until use.
Hybridization o f biotin-labeled probes (50 pg/1 ml) was performed at 56°C using the
Oncogene Sciences Hybridization System according to packaged instructions. Post
hybridization washes (low and high stringency) were also used as instructed.
A chemiluminescent detection method was used, which employs the substrate
CSPD (disodium 3-(4-methoxyspiro{l,2-dioxetane-3,2’-(5’chloro)tricyclo[3.3.1.l 3,7]
decan}-4-yl)phenyl phosphate) (Boehringer Mannheim catalogue number 1655 884).
Following the final post-hybridization wash, the membranes were washed in TBSTween 20 (100 mM Tris, 150 mM NaCl, 0.05% Tween 20 (v/v), pH 7.5) for 2-3
minutes at room temperature, followed by blocking with 3% bovine serum albumin
fraction V (Gibco catalogue number 11018-017) in TBS-Tween 20 for one hour at
65°C.
After removal o f the blocking agent by rinsing with TBS-Tween 20, the blot
was covered with streptavidin-alkaline phosphatase conjugate (Gibco catalogue
number 19542-018), 1 (ig/ml in TBS-Tween 20, and incubated for 10 minutes at
room temperature. The blot was washed three times with TBS-Tween 20 (5 minutes
each wash), and twice with detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, 50 mM
MgCfe, pH 9.5). The blots were spread with CSPD substrate diluted in the same
detection buffer, and heat sealed in a plastic sheet protector. After exposing the blot
to Kodak X-ray film for 15-30 minutes, the film was processed using Kodak D19
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developer and Kodafix fixative.

Reverse Dot Blot Analysis

With the reverse dot blot method, unlabeled oligonucleotide probes were
blotted onto the membrane. PCR was performed using biotin-labeled primers, and
the PCR products were hybridized to the probes on the membrane. The blotting,
hybridization, and detection were performed as described above except that 50 ng of
unlabeled probes were blotted onto the membrane in an array which allowed for
separate sections of the blot to be used for hybridization with each sample. Also, 75
pi o f biotin-labeled PCR product was used in 10 ml o f hybridization buffer.

Hybridization in a 96-Well Format

The reverse dot blot method was adapted to a 96-well format, using Nunc
CovaLinkNH microwell plates (124). With these plates, secondary amino groups are
positioned at the end of a linker, which is attached to the bottom of the wells. Single
stranded DNA can be covalently bound exclusively at the 5’ end by a
phosphoramidite bond (125). Denatured, unlabeled probes were applied to the plate
as described by the authors, 500 ng/well.
Biotin-labeled PCR products were denatured and hybridized to the coated
plates using the Roche Amplicor hybridization system.

All components for

denaturation, hybridization, and detection were supplied ready-to-use.

Washing

buffer was diluted as instructed. The product was used as described, except that the
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plates were sealed to prevent evaporation during hybridization, which was performed
overnight at 56°C.
Post-hybridization washing was performed using a BioTech microplate
washer.

A streptavidin-horseradish peroxidase conjugate (SA-HRP) was added,

allowed to bind the biotin, and the excess washed away. The biotin-bound SA-HRP
was detected using the substrate tetramethylbenzidine (TMB), which produces a blue
color when oxidized by HRP. The development was halted with the addition o f the
stop agent containing dilute HC1, which changed the color of the solution to yellow.
The plate was read in a BioTech model 340 microplate reader at the prescribed
wavelength of 450 nm. Absorbance readings were compared to known normal and
abnormal results.

Allele-Specific Polymerase Chain Reaction

For this study, a new approach for this method was developed, which made it
possible to detect any combination o f mutations in codons 12 and 13. With this
approach, codon twelve was analyzed in one direction, while codon 13 was analyzed
in the opposing direction. The outside positions (position 1 of codon 12 and position
2 of codon 13) were analyzed during the first round of amplification. Then, taking
the results of the first round into account, the inside positions were analyzed (position
2 of codon 12 and position 1 of codon 13). Figure 8 demonstrates this approach.
The design requires a minimum of 16 amplification reactions to analyze all
possible mutations in both codons. In order to accomplish this in an efficient manner,
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12a.

13a

13b

12b

Mutant-SpedUc Prftneis
PCRRo*xA2: tg gta gtt gga get am-------------->
P C R K on i 1 : tg gta gtt gga get k ------------- >
S .— ctt gtg gta gtt gga gct ggtgge gta ggc aag agt gcc ttg.— 3*
■*-------------- ag cat ccg ttc tea egg 'PCRRouMi I
*---------------aag cat ccg ttc teaegg :P C R R om i2
13b

Common Primers

Figure 8.

12b

5' eta ttg ttg gat cat att 3'

13a

5' gtactggtggagtattt3'

AS-PCR Opposing Primer Design for Codons 12 and 13.

the method was applied to a 96-well format. This allowed for the use of an 8-channel
pipettor for the addition of PCR mastermix, and arranged reactions of a single sample
alongside each other for further ease in pipetting. The design is shown in Figure 9.
The 16 mutant-specific and two common oligonucleotide primers were
synthesized

on

a

Perceptive

Biosystems

Expedite

8905,

using

standard

phosphoramidite chemistry. The ammonium hydroxide solution, used to elute the
primers from their columns was evaporated in a centrifugal vacuum concentrator. The
primers were resuspended in sterile water, and their concentrations and purity were
determined by measuring absorbances at 260 and 280 n m o n a spectrophotometer.
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PCR Mastermix Application
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PCR Amplification in a 96-Well Format.

PCR optimization was performed as described previously, using a Taguchi
array, except that 35 cycles of amplification were performed in 50 (il total volume
(additional reaction conditions: 2.5 Units Taq DNA polymerase, 10 mM Tris-HCl pH
8.3, 50 mM KC1, and 0.5 ng o f DNA extracted from fresh cells). No mineral oil
overlay was used, and amplification was performed in a Perkin Elmer model 9600
thermocycler. DNA was denatured for 5 minutes at 95°C, followed by 35 cycles of
PCR, and a final extension of 10 minutes at 72°C. Each cycle consisted of 30 seconds
at 95°C, 60 seconds at 52°C, and 30 seconds at 72°C.
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A commercially available PCR mastermix (Boehringer Mannheim catalogue
number 1636 103) was found to have the same concentrations as were determined to
be optimal, and was used in all subsequent experiments. A separate master mix was
prepared for each set of primers to be used. Each master mix was then aliquoted into
a 96-well tray, 40 pi per tube (final reaction conditions: 2.5 Units Taq DNA
polymerase in Brij 35, 0.005% (v/v), 0.2 mM each dNTP, 10 mM Tris-HCl, 50 mM
KC1, 1.5 mM MgCl2 , 1 pM each primer). Ten microliters o f DNA extract were added
to each tube immediately before amplification, which was performed as described
above.
PCR products were analyzed using

microplate array diagonal gel

electrophoresis (MADGE). The wells were formed in a diagonal 96-well array (using
a 96-pin bacterial replicator tool) to facilitate gel loading, capacity and interpretation.
Ten microliters of each PCR product were loaded onto the gel using a multichannel
pipettor. Electrophoresis was performed in a 2.0% Seakem GTG agarose gel in Tris
acetate EDTA (TAE) buffer containing ethidium bromide at 80 Volts for 40 minutes,
allowing for maximum separation without loss of product into another well.
The gels were photographed using a Polaroid camera with UV epiillumination. Presence o f PCR product identified a perfect match at the 3’ end of the
mutation-specific primer, and thus identified the nucleotide at the corresponding
position in the DNA. (With codon 13, the nucleotide identified was complementary
to the 3’ nucleotide of the primer.)
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Results

Hybridization Methods

All 14 patients who were analyzed with dot blot or reverse dot blot
hybridization had essentially the same result. Although the background hybridization
was greatly reduced with the reverse dot blot, single base discrimination was not
accomplished. The adaptation to the 96-well format was promising, but only one
tumor sample and two controls were processed, as the expense was found to be too
prohibitive. Although the PCR product could be stripped, and the coated plate used
again, the background increased with each trial.

Allele-Specific Polymerase Chain Reaction

The adaptation of AS-PCR used by this author proved to be highly successful,
with all o f the initial results being reproducible. A representative gel is shown in
Figure 10, which shows 24 patients analyzed for position 2 of codon 13.
Note that there is the possibility o f a mixed population o f cells, or different
mutations in each allele, resulting in multiple amplifications.

The wild-type

(guanine) reaction was used as an internal control, to assure that not only was there
amplifiable DNA present, but that the gene in question was amplifiable. A negative
result for the mutation specific reactions was only accepted if the wild-type reaction
amplified for that position.
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Figure 10.
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Mutant amplifications for adenine in samples 5, 11, 18 and 20.
Microwell Array Diagonal Gel Electrophoresis.

Discussion

It was this author’s intent to utilize a method of mutation detection that would
also serve to characterize the exact type and location of the mutation, eliminating the
necessity for additional analysis.

This eliminated several options, such as

immunohistochemistry, RNAse mismatch cleavage, mutant-enriched restriction
fragment length polymorphism, and single-stranded conformation polymorphism.
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These methods are only able to detect possible mutations. Further testing, such as
sequencing, would need to be employed to fully characterize the exact nature o f the
mutation, i.e., the location and type o f the mutation.
The use of archival material embedded in paraffin made other considerations
necessary. Only a minimal amount of each tissue sample could be used, in order to
allow for future analysis o f other genes from the same samples.
method employed required the use o f amplification.

Therefore, any

This eliminated the allele-

specific ligation assay, which did not employ amplification as described (116-118).
O f the remaining methods, direct sequencing was the best characterized in the
literature. However, this method was reportedly not able to detect mutations in tumor
ceils that make up less than 25% o f the total cells (96). Since microdissection would
not be employed to enrich for tumor cells, this level o f sensitivity was not acceptable.

Hybridization Methods

At the time that this project was undertaken, dot blot analysis was the best
characterized in the literature o f the remaining methods. Although none of the twelve
reports sited here discussed the sensitivity limit o f this method, reports that single
base substitutions could be discriminated made the method attractive (100).
However, this author found the method unable to detect mutations in a background of
normal cells, as all samples analyzed yielded the same hybridization pattern.
Since high background hybridization in non-isotopic dot blot analysis made
interpretation highly subjective, the author sought to use a less subjective method for

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

interpretation. The reverse dot blot method was adapted to a 96-well format, which
allowed final results to be analyzed in a spectrophotometric microplate reader.
Positive and negative results could then be assigned via numeric absorbance values.
In order to accomplish this, microplates needed to be coated with
oligonucleotide probes.

This presented a dilemma, since high stringency washes

were required for single-base discrimination. However, if the probes were not firmly
linked to the plate, they would wash away during this process. On the other hand, if
stringency were reduced to avoid this, background would increase both due to PCR
product adhering to the plate, and due to single base mismatches.
To solve this dilemma, a new product, the Nunc CovaLink NH plate was used.
This plate had a linker arm with a secondary amino group bound to the surface. DNA
probes were covalently linked to this amino group exclusively at the 5’ end, using
standard phosphoramidite chemistry as described by the manufacturer (125).
This method was satisfactory when used to evaluate the DNA sample and
controls used to evaluate the protocol, however the cost of the plates was prohibitive.
Also, this method was not able to detect multiple mutations in the same sample.
Therefore, this approach was abandoned.

Allele-Specific PCR With MADGE Analysis

The mutant-specific amplification method described by Stork et al. (89), had
potential for application to archived samples.

Since amplification and enrichment

occurred in a single-step, it was a very attractive option.
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Nonetheless, the method as described had flaws. The opposing approach for
codon 12 positions one and two seemed to solve the problem of a mutation in one
position interfering with the detection o f a mutation in the other position (Figure 6).
However, there was no provision made for mutations in codon 13, and a mutation
there would interfere with codon 12 position 2 detection. To resolve these issues, a
new approach was developed, which made it possible to detect any combination of
mutations in codons 12 and 13 (Figure 8).
A PCR optimization method employing a Taguchi’s array was used for all
amplifications during this project. Optimization experiments were performed using
DNA from fresh cells, to assure adequate specificity. Some authors have reported
decreasing the annealing temperature, or increasing the magnesium concentration in
amplification protocols with archival samples in order to increase the sensitivity.
However, either of these alterations decreases specificity, resulting in non-specific
annealing and non-specific PCR product. This author did not find this appropriate (or
necessary).

Conclusions

The adaptation of AS-PCR described by this author was determined to be the
best method for the detection and characterization of mutations in the K-ras gene.
Since enrichment for mutant sequences occurs during amplification, prior enrichment
for tumor cells by microdissection is not required. The method described is not able
to distinguish whether or not mutations detected concurrently in both codons 12 and
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13 occurred together on the same strand of DNA. However, the method is able to
distinguish whether or not two point mutations in the same codon (12 or 13) occurred
together on the same strand of DNA, making the correct assignment o f amino acids
possible.
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CHAPTER VI

ANALYSIS OF STUDY GROUP

Patient Population and Sampling Criteria

The study group consisted of patients who underwent surgery at Ferguson
Hospital between 1970 and 1983, and were subsequently diagnosed with Dukes’
Class B 2 or C2 colorectal carcinoma according to the modified Dukes’ classification
(3). According to this staging system, patients staged as Dukes’ B2 and C2 have
tumors that extend through the bowel wall. Dukes’ B2 patients have no identified
lymph node metastasis, while Dukes’ C2 patients exhibit metastasis in their regional
lymph nodes. Complete follow-up with accurate survival data was available for all
97 patients from the Ferguson-Blodgett Digestive Disease Institute’s colorectal
database. (A detailed data entry sheet can be found in Appendix B.)
Patients were chosen who had short-term survival (less than 5 years, with
death due to colon cancer), and who had long-term survival (greater than 10 years,
disease free). Any patients who died of causes other than colorectal carcinoma, or
who had other clinicopathological factors that may affect the data were excluded.
The study group o f 97 was divided into four cohorts: (1) 24 Dukes’ Class B2 patients
with short-term survival (less than 5 years), (2) 24 Dukes’ Class B2 patients with
long-term survival (greater than 10 years), (3) 24 Dukes’ Class C2 patients with short58
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term survival and (4) 25 Dukes’ Class C2 with long-term survival.
All paraffin blocks and corresponding hematoxylin-eosin stained slides were
obtained from the pathology archives of Ferguson Hospital.

Hematoxylin-eosin

stained slides were reviewed, and one paraffin block for each patient was chosen that
exhibited morphology consistent with the diagnosis. All paraffin blocks containing
lymph nodes were evaluated for each Dukes’ B2 patient who was found to have a Kras mutation in the tumor. During the test period (1970-1983) mesenteric clearing of
lymph nodes was practiced, assuring the examination o f all regional lymph nodes in
this study.

Sample Preparation

A single 10 micron-thick section was removed from each paraffin block using
a disposable microtome blade, and placed into a sterile microcentrifuge tube. All
instruments were thoroughly cleaned with chlorine bleach followed by ethanol, and
gloves were changed between each sample to prevent cross-contamination. Sterile,
ultrafiltered, deionized water was added to each tube in the volume of 100 pi. The
tubes were sealed and heated at 95°C for 15 minutes, and briefly centrifuged to
collect the sample into the bottom o f the tubes, followed by cooling for 10 minutes at
4°C. The supernatant was transferred to a second sterile tube, and stored at -70°C
until use.
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K-ras Mutational Analysis

The tumor DNA extracts were analyzed using allele-specific polymerase
chain reaction (AS-PCR) and microplate array diagonal gel electrophoresis
(MADGE) as described beginning on page 48.
All Dukes’ B2 patients who were found to have mutations in their tumors were
analyzed further. DNA was extracted from each block o f lymph nodes and analyzed
individually to determine if the same mutation could be identified.

Statistical Analysis

Statistical analysis was performed using SPSS software. Chi-squared analysis
was used to determine whether or not differences exist in age, sex, surgeon, site of
primary tumor, histopathological grade, Dukes’ classification, and K-ras mutation
incidence, location, or type between the two survival groups (p < 0.05).
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CHAPTER V n

RESULTS

Characteristics of Sample

Complete data at all four nucleotides were obtained for 89 o f the 97 patients
tested (92%). The group of 89 patients consisted of 44 males and 45 females, with
ages ranging from 34 to 88 years, and a mean age of 64 years. The tumors were
located at the rectosigmoid junction in 68 patients and in the rectum in 22 patients.
(One patient had synchronous lesions in both locations.) There were 45 Dukes’ B2
patients and 44 patients classified as Dukes’ C2 colorectal adenocarcinoma.

The

short-term survival group consisted o f 42 patients, while the long-term survival group
consisted of 47 patients.

Using Chi-squared analysis, there were no significant

differences found in age, sex, surgeon, site of tumor, histological grade, or Dukes’
classification between the survival groups (p < 0.05).
The subgroup of Dukes B2 patients consisted of 21 males and 24 females, with
ages ranging from 34 to 88 years, and a mean age of 67 years. There were 20 patients
with survival less than five years, and 25 patients with survival greater than 10 years.
The tumors were located at the rectosigmoid junction in 36 patients and in the rectum
in 10 patients. (One patient had synchronous lesions in both sites.) Chi-squared
analysis revealed no significant differences found in age, sex, surgeon, site of tumor,
61
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histological grade, or Dukes’ classification between survival groups (p < 0.05).

Analysis o f Mutations in K-ras Exon 1
Analysis o f DNA From Tumors

AS-PCR was highly successful when applied to archival material, with 92%
(89/97) of samples being amplified at all 4 nucleotide positions analyzed. In codon
12, there were 9 glycine*^aspartic acid mutations, 6 glycine-^valine mutations, 1
glycine-^arginine mutation, and 1 glycine-^cysteine mutation. In codon 13, there
were 37 glycine-^aspartic acid mutations, 4 glycine-^ serine mutations, 1 glycine*^
cysteine mutation, and 1 glycine-^ alanine mutation.
O f these mutations, 4 patients had multiple mutations in the same codon (1
patient had valine and cysteine at codon 12; 1 patient had aspartic acid, serine, and
cysteine at codon 13; and 2 patients had aspartic acid and serine at codon 13). Eleven
patients had mutations in both codons (8 patients with aspartic acid at both codons,
and 3 patients with valine at codon 12 and aspartic acid at codon 13).
There were no significant differences in mutational frequencies between
tumor stages (Table 6). This table presents the total number of patients by mutation
location, not the total number of mutations by location. (Note that this differs from
the number o f each type of mutation shown above. In cases with multiple mutations,
the patient was counted only once for this table.) No significant relationship was
found between survival and the presence or absence of a single mutation in either
codon. However, colorectal cancers with concurrent mutations in codon 12 and 13
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occurred significantly more frequently in long-term compared to short-term survivors
(21.3% versus 2.4%).

Table 6
Patients With Mutations by Location
Group

None

Codon 12

Codon 13

Codons 12 & 13

b2

51.1% (23)

2.2% (1)

35.6% (16)

11.1% (5)

C2

50.0% (22)

9.1% (4)

27.3% (12)

13.6% (6)

< 5 Years

57.1% (24)

11.9% (5)

28.6% (12)

2.4% (1)*

> 10 Years

44.7% (21)

0% (0)

34.0% (16)

21.3% (10)*

* p < 0.05 Chi Square 5 year versus 10 year

Analysis of the types o f mutations showed that glycine-^aspartic acid
mutations in either codon were related to long-term survival (Tables 7 and 8). (Totals
for these tables were tallied as described for Table 6, above. If there were multiple
mutations, and one was aspartic acid, the patient was counted as ‘aspartic acid’ and
not as ‘other mutation’.) Further, 8 o f the 10 long-term survivors with mutations in
both codons had aspartic acid substitutions in both codons.

Analysis of Dukes’ Class B? Patients for Micrometastasis

Only Dukes’ B2 patients were analyzed further to detect micrometastasis. It
was not necessary to analyze Dukes’ C2 patients, since metastasis was already
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Table 7
Patients With Codon 12 Mutations by Type

Group

Other Mutation

Aspartic Acid

No Mutation

b2

11.1% (5)

2.2% (1)

86.7% (39)

c2

9.1% (4)

17.6% (6)

77.3% (34)

< 5 Years

2.4% (1) *

11.9% (5)

85.7% (36)

> 10 Years

17.0% (8)*

4.3% (2)

78.7% (37)

* p < 0.05 Chi Square 5 year versus 10 year

Table 8
Patients With Codon 13 Mutations by Type

Aspartic Acid

Other Mutation

No Mutation

b2

42.2% (19)

4.5% (2)

53.3% (24)

c2

40.9% (18)

0% (0)

59.1% (26)

< 5 Years

31.0% (13)*

0% (0)

69.0% (29)

> 10 Years

51.1% (24)*

4.2% (2)

44.7% (21)

Group

* p < 0.05 Chi Square 5 year versus 10 year

detected by histological examination of the lymph nodes.
DNA was successfully amplified at both codons in all 45 tumor specimens.
Mutations were detected in 49% (22/45) of the specimens (Table 9).

(Data are
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presented as described for Table 6 above.) In codon 12, there were 5 glycine-^
aspartic acid mutations, 1 one glycine-^valine mutation. In codon 13, there were 19
glycine-^aspartic acid mutations, 4 glycine*^serine mutations, and 1 glycine-^
alanine substitution. Three patients had multiple mutations in codon 13 (1 patient had
aspartic acid, serine, and cysteine; and 2 patients had aspartic acid and serine), while
5 patients had aspartic acid mutations at both codons.

Table 9
Dukes’ B2 Patients With Mutations in Tumors by Location

None

Group

Codon 12

Codon 13

30.0% (6)

< 5 Years

65.0% (13)

5.0% (1)

> 10 Years

40.0% (10)

0% (0)

40.0% (10)

Codons 12 & 13

0%(0)
20.0% (5)

O f the 22 patients identified with mutation-positive tumors, mutational status
o f lymph nodes was evaluated in 20. (One patient was eliminated due to lack of
archived lymph nodes, and amplifiable DNA was not obtained from a second
patient’s lymph nodes.) This group of 20 patients consisted o f 11 males and 9
females, with ages ranging from 52 to 83 years, and a mean age o f 65. Tumors were
located at the rectosigmoid junction in 16 patients, and in the rectum in 4 patients.
There were 6 patients in the short-term survival group, and 14 patients in the long
term survival group.
The incidence of mutations in the lymph nodes in this group was 80% (16/20)
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(Table 10). (Data for Table 10 are presented as described for Table 6 above.) In
codon 12, there was 1 glycine-^aspartic acid and 1 glycine->valine mutation. In
codon 13, there were 15 glycine-^aspartic acid and 2 glycine-^serine mutations.
Two patients had multiple mutations in codon 13 (aspartic acid and serine), and 1
patient had aspartic acid mutations at both codons.

Table 10
Dukes’ B2 Patients With Mutations in Lymph Nodes by Location
None

Group

Codon 12

Codon 13

Codons 12 & 13

< 5 Years"

0% (0)

10.0% (1)

90.0% (5)

0% (0)

> 10 Years

28.6% (4)

0% (0)

64.3% (9)

7.1% (1)

All 4 patients with mutation-free nodes were disease-free after 10 years (mean
survival at last follow-up = 1 9 years), while 37.5% (6/16) of the patients with
mutation-positive nodes died as a result of their disease within five years. (Statistical
analysis was not performed, due to the small sample size.)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER V m

DISCUSSION

K-ras Tumor Status as a Prognostic Marker

The results o f this study are consistent with the reported incidence o f K-ras
mutations in colorectal cancers o f 40-60%. The most frequent mutations appear to be
those resulting in the substitution of aspartic acid for glycine at either codon 12 or 13,
as others have also reported (62,71,84,113).
Benhattar et al. (78) reported a significantly higher incidence of mutations in
recurrent (71%) versus disease-free patients (25%), and mutations other than
glycine~>aspartic acid were correlated with very high risk for recurrence, indicated
that replacement by aspartic acid was related to longer survival than replacement by
other amino acids. Although the findings in the current study did not correlate amino
acid substitution other than aspartic acid with poor survival, the data did show
survival advantages with aspartic acid rather than other amino acids (Tables 7 and 8).
The differences between the current study results and those o f Benhattar et
a/. (78) may be attributed to differences in the selection of sub-groups, i.e., the
selection of patients who were obviously cured of the disease (greater than 10 year
survivors) and those who lived for less than five years may have exaggerated
differences in biological tumor aggressivity. Like the current study, Benhattar et al.
67
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employed AS-PCR for mutation analysis.

However, they used a unidirectional

approach that would not have allowed the detection of a double mutation.
Finkelstein et al. (84) reported that tumor recurrence patterns seem to
correlate with K-ras mutation patterns—that is, local recurrence was associated with
lower incidences of mutation compared to tumors complicated by hematogenous
spread. They also identified aspartic acid substitutions at codon 13 as prognostically
favorable (62,84). However, a codon 12 mutation resulting in aspartic acid or any
other amino acid correlated with a very poor prognosis (62,84).
The data from the present study showed similar results to the genotyping of
tumors performed by Finkelstein (84), with aspartic acid substitution being the most
frequent alteration at either codon. The results in Table 8 agree with Finkelstein’s
finding that mutations resulting in aspartic acid substitutions at codon 13 were
prognostically favorable. However, in the current study no significant differences
were identified in the incidence of K-ras mutations with respect to survival status
(less than five year--43%; greater than ten year~55%), or between Dukes stages (B2~
49%; C2—50%).
Unlike the Finkelstein (83) report, with the use of more locally advanced
tumors that differed only by the presence or absence o f lymph node metastases
(Dukes B2 and C2), the effect of isolated hematogenous spread of the disease was not
evaluated here. Also, the current study identified a significantly higher incidence of
aspartic acid substitutions at codon 12 in the greater than 10-year survivors compared
to those with early recurrence (Table 7). However, this finding has been reported
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before by Moerkerk et a l (72). They reported that, in a group of Dukes’ class B and
C colorectal cancers, aspartic acid at either codon was not associated with metastasis,
whereas alanine or cysteine at codon 12 or arginine at codon 13 was associated with
metastasis.
The current project identified an additional subset of patients with concurrent
mutations at codon 12 and 13 in the long-term survivors group, with the most
frequent pattern being replacement with aspartic acid at both locations (80%). Thus it
appears that aspartic acid at codon 13 confers significant survival advantage to
patients with colorectal cancer, which is enhanced by concurrent substitution of
aspartic acid at codon 12.
Although the specific role that mutations in p21ras play in colorectal cancer
development and subsequent tumor aggressivity remains unclear, there are several
potential mechanisms o f action. The net result of mutations at codon 12 or 13 is
decreased intrinsic hydrolysis rate of GTP by 10-fold due to alterations in the spatial
interaction with the phosphate groups (21), resulting in significant prolongation of
protein activity. Alternatively, p21ras proteins that contain aspartic acid substitutions
at codon 13 are capable of inducing T-lymphocyte response (126). Activation of
these T-lymphocytes has been associated with a predominance of early stage
carcinomas (127), which may account for the improved survival and lower recurrence
rates in tumors with aspartic acid mutations at codons 12 and 13 identified both in the
present study and by others (119).
The results of this study confirm that K-ras mutations occur in approximately
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50% of sporadic colorectal carcinoma. The frequency o f K -ras mutations did not
differ between tumor stages (B2-49%; C2-50%), nor does the presence or absence o f a
mutation distinguish between patients with short term (43%) versus long-term (55%)
survival.

However, the presence of specific mutational patterns, particularly

concurrent mutations leading to aspartic acid substitutions at codon 12 and 13,
conferred a significantly higher likelihood of surviving longer than 10 years
following resection o f colorectal cancer.
K-ras Lymph Node Status as a Marker for Micrometastasis
There have been other methods used to identify micrometastases in lymph
nodes of patients with colorectal cancer. Greenson et al. (128) and Cutait et al. (129)
independently reported the use of immunohistochemical staining for cytokeratin as a
means of identifying micrometastases in hematoxylin-eosin negative lymph nodes.
Using this method, Greenson et al. (128) upstaged 28% of Dukes B colorectal
cancers.

However, their findings that micrometastases correlated to survival

contradicted those of Cutait et al. (129), who found micrometastases in 26% of Dukes
B patients, but found no correlation to survival.
Unlike cytokeratin staining, which is only able to distinguish that cells are of
epithelial origin, the method reported here uses a specific pattern o f mutations found
in the tumor cells as a marker to identify micrometastasis. For this to be a valid
indicator, histologically positive metastasis should have mutational patterns that
match that of the associated tumor.
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Losi, Benhattar, and Costa (67) reported that point mutations found in
metastatic lesions, as well as those found in local recurrence, were identical to those
found in the primary tumor. This was the case even when the recurrence was found
up to five years after treatment for the primary cancer. Dix et al. (36) reported a
similar finding in cases with lymph node and liver metastasis.
These findings, as well as evaluations of clonal progression within the primary
lesions, support the use of oncogenic markers of disease progression (57). When
heterogeneity was identified, it was in the form o f an addition mutation at the point of
deepest invasion, interpreted as a subclone of the original (38). However, even in
these cases, the original mutation was also identified.
Together, these findings suggest that, even if further mutations occurred
during progression of the disease, the mutation found within the tumor would be
found in the metastatic lesions. It would, therefore, make sense to analyze the most
common site of metastasis (the lymph nodes) for evidence o f disease spread.
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CHAPTER IX

CONCLUSIONS

This study confirmed that the presence of aspartic acid substitution at either
codon 12 or 13 is a positive prognostic marker in colorectal cancer. Additionally, a
new group was identified with concurrent mutations in both codons 12 and 13, which
was significantly associated with long term survival.
Using K-ras mutation as an indicator of micrometastases, 35% (16/45) of
Dukes’ B2 colorectal cancers were upstaged in the current study. Further, the absence
of identified micrometastases by this method was a very favorable indicator of
prognosis, with no recurrence after an average o f 19 years. Since mutations occurred
in 49% (22/45) of the Dukes’ B2 tumors, the method described here provides a tool to
further evaluate approximately half of all Dukes’ B colorectal cancers.
The evaluation of mutational status of other genes along with K-ras would
provide a molecular ‘fingerprint’ of the tumor, which could be used to more clearly
identify micrometastases in all Dukes’ B colorectal cancers. Since K-ras and/or p53
mutations have been found to occur in the vast majority of colorectal cancers
(95, 111), p53 would be a good candidate for additional screening.
The author suggests expanding the study to a larger group for confirmation of
the findings, followed by prospective studies to evaluate the benefit of additional
treatment for Dukes’ B patients identified as high risk by this method.
72
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1
2
3

R EM ************PROGRAM FOR PCR OPTTMIZATTON************
R E M CALCULATION OF SIGNAL TO NOISE RATIO (SNL) FO R PCR REACTION COMPONENTS
R EM THE OPTIMAL LEVEL FOR A COMPONENT IS TH E LEVEL YIELDING THE HIGHEST SNL

“*»****»*»***p c r OPTIMIZATION USING MODIFIED TAGUCHI METHOD***********'

11
12
13
14
15
16

PRINT
PRINT
PRINT
PRINT
PRINT
PRINT

21

22
23
24

PRINT
PRINT
PRINT
PRINT

“
YOU WILL BE ASKED TO INPUT THREE VALUES.”
“TH ESE M U ST CORRESPOND TO THE DNA YIELDS OF THE PCR REACTIONS”
“
IN W HICH THIS COMPONENT WAS TESTED A T THE LEVEL SHOWN.”

31
32
33
34
35
36
37

PRINT
INPUT
PRINT
INPUT
PRINT
INPUT
PRINT

“INPUT THE FIRST YIELD A T LEVEL 1”
A1
‘IN P U T THE SECOND YIELD A T LEVEL F
BI
“INPUT THE THIRD YIELD A T LEVEL 1”

“THIS PROGRAM WILL COMPUTE THE SIGNAL TO NOISE RATIO FOR A SINGLE”
“
COMPONENT A T THREE LEVELS AND CHOOSE THE OPTIMAL LEVEL.”
“IT ASSUMES THAT FOUR COMPONENTS WERE TESTED A T THREE LEVELS EACH.”

Cl

41 PRINT “INPUT THE FIRST YIELD AT LEVEL 2”
42 INPUT A2
43 PRINT “INPUT THE SECOND YIELD AT LEVEL 2”
44 INPUT B2
45 PRINT “INPUT THE THIRD YIELD AT LEVEL 2”
46 INPUT C2
47 PRINT
51 PRINT “INPUT THE FIRST YIELD AT LEVEL 3”
52 INPUT A3
53 PRINT “INPUT THE SECOND YIELD AT LEVEL 3”
54 INPUT B3
55 PRINT “INPUT THE THIRD YIELD AT LEVEL 3”
56 INPUT C3
57 PRINT
61 SNL1 = -10 * LOG(1 / 3 * (1 / (A1 * Al) + 1/(B l * Bl) + 1/(C l * C l)))/2.3
62 SNL2 = -10 * LOG(l / 3 * (1 /(A2 * A 2)+ 1 / (B2 * B2)+ 1 /(C2 * C2)))/2.3
63 SNL3 = -10 * LOG (1 / 3 * (1 / (A3 * A3) +1 / (B3 * B3) +1 / (C3 * C3))) / 2.3
71 PRINT “THE SIGNAL TO NOISE RATIO AT LEVEL 1 = ”, SNL1
72 PRINT “THE SIGNAL TO NOISE RATIO AT LEVEL 2 = ”,SNL2
73 PRINT “THE SIGNAL TO NOISE RATIO AT LEVEL 3 = ”,SNL3
74 PRINT
81 IF SNL1 > SNL2 AND SNL1 > SBL 3 THEN
82 PRINT “THE OPTIMAL LEVEL FOR THIS COMPONENT IS LEVEL I”
83 ELSEIF SNL2 > SNL1 AND SNL2 > SNL3 THEN
84 PRINT “THE OPTIMAL LEVEL FOR THIS COMPONENT IS LEVEL 2”
85 ELSE PRINT “THE OPTIMAL LEVEL FOR THIS COMPONENT IS LEVEL 3”
86 END IF
91

END
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COLORECTAL CANCER
Data Entry Form
Demographics

Last N am e

First Nam e_____________________________

A ddress_____________________________________________ _
City, State, Z ip _______________________________________________
Area C o d e

Phone# __________________________

B irthdate______________________________

Hosp # ______________________________

Sex

M

F

Race

White/Caucasian
Black/African American
American Indian/Alaskan Native
Other

Hispanic/Latin
Not Stated

Asian/Asian American
Multiracial

Date Diagnosed with CRC

Pre-existing Medical Conditions
Thyroid
CUC
Crohn’s
Diabetes
Cirrhosis

Hypertension
MI
CHF
Heart Disease
Bleed Disorder

Cardiac Arrhythmia
CVA/TIA/Stroke
COPD
Prior Cancer
Cancer after Primary

List Other Pre-existing

Follow Up
Last follow-up date.
Death

Y

Death due to CRC?
Death Cause

If dead, was autopsy done?
N

Y

Date Last Letter Sent
Y

Hemorrhage

N

Unknown
Cardiac Sepsis

Other

If other list cause ___________________
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Visits

Date Reviewed

Date o f Visit
Account #

Classification of CRC Visit
Primary CRC
Metachronous CRC
Recurrent CRC
Appendiceal Primary
Metachronous non-CRC
Other, Please specify_____

Lap (see lap instructions)
GI Bleed (Embolization Study)
Fresh Tissue, pending
Primary non-CRC
Recurrent non-CRC

Type of Visit

Hospital

SURGICAL admission. Hosp. chart available
SURGICAL admission. Hosp. chrt not available
MEDICAL admission. Hosp chrt available
MEDICAL admission. Hosp. chrt not available
OFFICE visit/Telephone f/u
DIAGNOSTIC testing independent of office visit

Yes - Ferguson Clinic chrt
No - Ferguson Clinic chrt
BMMC
BWH
SMH
Metro
Other

Principal Surgery

Rt. Hemi
Lt. Hemi
Total Colectomy
Anterior/Sigmoid Resection
Low Anterior Resection
LowLAR
M id LAR
H ighLA R
APR
None - Unresectable
TRE, Fulguration

Colotomy, Polypectomy
Bx. Only (refuse surg)
Small Bowel Resection
Hartmann
Ostomy Closure
Ostomy Formation
J Pouch
Proctocolectomy
Proctectomy
Subtotal Colectomy
S Pouch
Other Surgery_________

(include appendix,gallbaldder,etc.)
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Ferguson Clinic Surgeon

M azier
MacKeigan
Talbott

Luchtefeld
Senagore
Surrell

General Surgeon
Post, Kenneth
Zadvinskis, Ivars
W ilcox, Richard
Johnson, Greg
DeVries, Daniel
Rodriguez, Carlos
Lovell, Raymer

Stawski, W illard
Sherman, Stanley
Gladding, Sandra
Borreson, Daniel
Passinault
Other surgeon____

Surgery Variables
Colostomy

Y

Ileostomy

Y

Elective

N
N

Blood Loss
Brook

_(ml or cc) *op report

Continent (Kock,Barnett)

Em ergent (circle)

Anastomic Technique
Stapled
Stapled EEA
Stapled GIA
HS 1 layer > interrupted
HS 1 layer - continuous
HS 2 layer - interrupted
HS 2 layer - continuous

Surgery. Other
Posterior Vaginectomy
Hysterectomy
Oophorectomy
Pelvic Exenteration

HS 2 layer - inter & continuous
HS 1 layer - inter & continuous
No Anastomosis (colostomy, hartmann)
S/S Hand Sewn
E/E Hand Sewn
E/S Hand Sewn

Tumor Extension at Surgery (op report)
Residual Tumor
Liver Metastasis
Peritoneal Spread
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Time Study
Emergency Room Admit Y

N

Critical Path

Date of Admit

Time o f Admit

Date of surgery

Time Proc Start to Proc End

Date of Discharge

□
Jcase log)

Time o f Discharge_

Hematology
CEA Preop

CEA Postop _
(2 wks £ x £ 3 mo)

Transfusions
Did patient receive a blood transfusion?

Y

N

If No, do not answer any of the questions below.

Preop Y N
( 2 days <x<lwk preop)

Periop Y
(± 2 days)

N

Postop
Y N
C> 2 days postop)

(Total units) Platelets
PRBC’s '
Plasma

Poston Complications
UTI
Atelectasis
Pneumonia
Cardiac Arrythemia
MI
Sciatica
Pulmonary Emboli
Renal Failure

CHF/Cardiac Failure
Wound infection___
Dehiscence
Ileus
Bowel Obstruction
Inop Comp________
TIA/CVA/Stroke
Postop Bleed

jCsite)

_(site)

Septicemia_
Respiratory Distress
Intrabd. Abscess
Stenosis
Anastomotic Leak
DVT
Other_________

Preop Diagnostics
Barium Enema
Flex Scope
Colonoscopy
Biopsy
Sigmoidoscopy
Retinoscopy
EGD
UGI

Abdomen
CT
IVP
Ultrasound
IRUS
Gastrograffin
O th e r_____

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

_(site)

Anesthesia
ASA status (circle one) I
Type o f Analgesia

H

HI

General

IV

V

El

EH

EHI

EIV

EV

General/Epidural Spinal

Postop Analgesia (Circle all that apply for the FIRST THREE DAYS POSTOP)

IM

PCA

EPI

Pathology I
Path Num ber_____________________ _________ __
Any hx o f metachronous lesions? Y N
# of Synchronous (more than one) colorectal CA’s _______

Site O ne
Fresh tissue Y
N
Distance from anal vereefcml

Distance from anal verge(cm)
♦(see definitions below)
♦Site 2
List other site

♦Site 1
List other site
•C E C U M
RECTUM

Site Two

A SC , R T , H E PA T IC F L E X
T R A N SV E R SE
D E SC , S PL E N IC F L E X
S IG M , R E C T O SIG M O ID
IL E U M
PO U CH
STOM ACH
DUODENUM
D U O D E N A L P A P IL L A
Other
NONE

♦Histology
List other Hist

♦Histology
List other Hist
•A D E N O C A R C IN O M A
V ILL O U S A D E N O M A
HAM ARTOM A

A D E N O M A - N O T SPEC IFIED
TUBULAR ADENOM A
L Y M PH O ID
H Y PE R PLA ST IC /M E T A PLA STIC

T U B U L O V ILL O U S A D E N O M A
FU N D IC G L A N D /C Y S T IC

Other

♦Histologic Grade

♦Histologic Grade
♦Well

Moderately

Poorly

Undifferentiated

(Site I)

(Site 2)

Total Nodes Found____________
Total Nodes Positive___________

Total Nodes Found__________
Total Nodes Positive___________

Vessel Invasion
Nerve Invasion
M ucin Production
Lesion Size_______ (cm)

Vessel Invasion
Nerve Invasion
Mucin Production
Lesion Size________ (cm)

PLEASE NOTE IN COMMENTS IF LYMPHANGUIC INVASION IS NOTED AND NODES POSITIVE = O
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Site Three

Site Four

Distance from anal verge(cm)

Distance from anal verge(cm)

•(see definitions below )

♦Site 3
List other site
•C E C U M
RECTUM

♦Site 4
List other site

A S C ,R T , H E P A T IC F L E X
TRANSVERSE
D ESC , S P L E N IC FL E X
S IG M , R E C T O SIG M O ID
IL E U M
POUCH
S TO M A C H
DUODENUM
D U O D E N A L P A PIL L A
Other
NONE

♦Histoloev
List other H ist

♦Histology
List other Hist

A D E N O C A R C IN O M A
V ILLO U S A D E N O M A
HAM ARTOM A

A D E N O M A -N O T SP E C IF IE D
TUBULAR ADENOM A
L Y M PH O ID
H Y PE R PL A ST IC /M E T A PL A ST IC

T U B U L O V ILL O U S A D E N O M A
FU N D IC G L A N D /C Y S T IC

Other

♦Histologic Grade

♦Histologic Grade
♦Well

Moderately

Poorly

Undifferentiated

Total Nodes Found _
Total Nodes Positive

Total Nodes Found _
Total Nodes Positive

Vessel Invasion
Nerve Invasion
Mucin Production
Lesion S iz e _____

Vessel Invasion
Nerve Invasion
Mucin Production
Lesion Size_____

_(cm)

Are there anv additional sites not entered?

Y

_(cm)

N
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TNM Gassification
TX: Primary tumor cannot be assessed, ie. no specimen
TO: No evidence o f primary tumor, ie. no cancer found in specimen
Tis: Carcinoma in situ , ie. cancer in polyp, no invasion into wall
T l: Invades mucosa, submucosa, ie. Duke’s A
T2: Invades into, but not through muscularis propria, ie. Duke’s B l,C i
T3/T4:
See below
Serosa (sm all bowel, colon, proxim al (upper) one-third of rectum)
T3:
invades through muscularis propria (B2,C2)
-into subserosa
-into, but not through serosa
-into pericolic fat, perirectal fat, soft tissue
T4:
invades through serosa
-into free peritoneal cavity
-into contiguous\adjacent organ (vagina,prostate,ureterjddney)
No Serosa (distal (lower) tw o-thirds of rectum )
T3: invades through muscularis propria (B2,C2)
-into pericolic fat, perirectal fat, soft tissue
T4:
invades into contiguous/adjacent organ (vagina,prostate,ureter,kidney)

NX:
NO:
N1:
N2:
N3:

Regional lymph nodes cannot be assessed, ie. no specimen
No regional lymph node metastasis, ie. no positive nodes, Duke’s A or B
1 to 3 positive pericolic or perirectal lymph nodes, ie. Duke’s C
4 or more positive pericolic or perirectal lymph nodes, ie. Duke’s C
Positive/”enlarged” lymph nodes along the course of a named vascular trunk, ie. along the aorta
(periaortic), celiac axis. Positive apical/apex nodes should be referred to AJS for staging

MX:

Distant metastasis cannot be assessed. Pathologist usually stages as MX because there is no biopsy
or tissue to stage. Distant metastasis should be assessed based on intraoperative findings, CT
reports, x-rays, etc.
No distant metastasis
Distant metastasis, ie. liver, lung, INCOMPLETE excision/resection o f peritoneal spread, small
bowel mesentery, etc. Duke’s D. Any spread in question should be referred to AJS.

MO:
M l:

Duke’s Ci (T2NiM o)
Duke’s Ci (T2N 2Mo)
Duke’s C2 (T3N1M0)
Duke’s Cz (T3 N2 Mo)

Duke’s A (T,NoM o)
Duke’s BiCr2 NoMo)
Duke’s B2 (T3N0M0)
Duke’s B3 (T 4 N0 M0 )

(site I)

Flow Cytometry

Duke’s C 3 (T4N,M o)
Duke’s C3 (T4N2M0)
Duke’s D (T7N7M1)

(site 2)

Y

N

Flow Cytometry

Y

N
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NG/Diet/Bowel Functions
NG
NG mop and stays?

Y

N

NG inserted postop? Y

Date removed

N

Date inserted

Diet

Date removed

Bowel Functions

Date Clear liquids_________

Date Flatus____

Date Full liquids___________

Date B M _____

Date General/Post-Surgical Soft_______________________________
If not stated, please make note in comments.
T em perature
MIN POD #1
MAX POD #1
MIN POD #2
MAX POD #2
MIN POD #3
MAX POD #3
MIN POD #4
MAX POD #4
MIN POD #5
MAX POD #5
Treatm ent fo r CRC *hx, phy exam
XRT for primary disease?

Preop or Postop

None

Preop

Preop or Postop

None

Postop

Preop & Postop

XRT Dosage (cGY)____________
XRT after recurrence?

Y

N

Chemotherapy for primary disease?
Chemo after recurrence?

Y

Preop

Postop

Preop & Postop

N
T reatm ent fo r Non-CRC

XRT for Non-CRC

N

Chemo for Non-CRC

N

List S ite_________
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A dditional D ata Collection for Laparoscopic Patients!
Technique:

Lap

Converted Lap

Indication:
Adenocarcinoma
Diverticular Disease
Appendicitis
GI Bleed
Adenoma
Volvulus
IBD (Crohn’s, CUC)
Rectal Prolapse
Other
Intraoperative Comps:
Hemorrhage
Hypotension
Hypoventilation (? EtOH<=40)
Acidosis(l=metab 2=resp 3=mixed)
Enterotomy
Reasons fo r Conversion:
Adhesions
Bleeding
Perforation
Unfavorable Conditions

Anastomosis:
Intracorporeal
Combined Intra/Extracorporeal
Assistant:

(please list)

Pathology:
Lesion Length.
Bowel Length.
Crohn’s
CUC
Appendicitis
Div-itis
Div-osis
Other Path
O ther Postop Comps:
Laparotomy for Bow Obst

O ther Surgical:
Ureteral Catheter
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PHYSIOLOGICAL SCORE (preoperative evaluation)
(plttM writ* la actaal vala«)

1

2

Age (years)

£60

61-70

£71

Cardiac signs

no failure

diuretic, digoxin, antianginal
or hypertensive therapy

peripheral edema;
warfarin therapy

aised jugular venous
pressure

borderline cardiomegaly

cardiomegaly

SOB/dyspnea on exertion

SOB/dyspnea
(one flight stairs)

SOB/dyspnea at rest
(rate £30/min)

mild COAD (COPD)

moderate COAD

fibrosis or consolidation

£89

Chest X-ray
Respiratory history

no SOB/dyspnea

Chest X-ray

8

4

(chronic obstructive airwiy diseue - chronic obstructive pulmorury disease)

Blood pressure (fy,,oiic.IO|>)
(mmHg)

110-130

131-170
100-109

£171
90-99

Pulse (beats/min)

50-80

81-100
40-49

101-120

£121
£39

Glasgow coma score

15

12-14

9-11

£8

Hemoglobin (g/lOOml)

13-16

11.5-12.9
16,1-17.0

10.0-11.4
17.1-18.0

£9.9
£18.1

4-10

10.1-20.0
3.1-4.0

£20.1
£3.0

BUN (mg/dl)
(mEq/L)

£45
£7.5

46-60
7.6-10.0

61-90
10.1-15.0

£91
£15.1

Sodium (mmol/1)

S I 36

131-135

126-130

£125

(Hgb)

White cell count (xlOl2/ l )
(WBC)

(N»)
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OPERATIVE SCORE (postoperative evaluation)
1
Potassium (mmol/1)
Ob

3.5-5,0

Electrocardiogram(EKG)
(EKG=ECG)

normal/
not done

2
3.2-3.4
5.1-5.3

2.9-3.1
5.4-5.9

£2.8

atrial fibrillation
(rate 60-90)

any other abnormal
rhythm or £5
ectopics/min Q waves
or ST/T wave changes

major

major +

2

>2

(pleue write out tesutti if undev)

£ 6 ,0

Operative severity

minor

Multiple procedures

1

Total blood loss (ml)

£100

101-500

501-999

£1000

Peritoneal soiling

none

minor (serous fluid)

local pus
or blood

free bowel content, pus

Presence o f malignancy

none

primary only

nodal metastases

(no positive nodei)

(tny poiitive nodes)

distant metastases
(je. liver nreti)

(op report)

(pith report)

Mode o f surgery

elective

moderate

8

4

emergency resuscitation
of> 2h possible
Operation <24h after admission

emergency (immediate
<2h needed)

Appendix C
Molecular Data Collection Worksheet
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Molecular Biology Laboratory
Fergiuon-Blodgett Digestive Disease Institute
Research Department
K-ras mutation specific PCR results
Result
Wild
Type
Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third

Codon 12 base
Codon 12 AA
Position 1 Position 2
G
G
Gly

Codon 13 base
Codon 13 AA
Position I Position 2
G
G
Gly

Sample M first
second
third
Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third

Sample #

first
second
third
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Ferguson Hospital Surgical Consent
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FERGUSON
HOSPITAL
72 SHELDON BLVD. S E - GRAND RAPIDS, MICHIGAN 49503

PRO CEDURE CO N SEN T FORM
L.

I hereby authorize_____________________________M.D. and whomever he may
designate as his assistant to perform the following contemplated procedure and/or
procedures:________________________________________________________
at Ferguson Hospital.

2.

If any unforeseen condition(s) arises in the course of the procedure, I further request and
authorize the physician to do procedures in addition to or different from those now
contemplated, if in the physician’s judgement he deems it advisable.

3.

I acknowledge that the contemplated procedure, possible procedures in addition to the
contemplated procedure, possible complications, and risks involved, have been explained to
me by the physician to my satisfaction.

4.

I acknowledge that alternative methods of treatment have been discussed w ith me by the
physician to my satisfaction.

3.

I acknowledge that no guarantee or assurance has been made as to the results that may be
obtained. I understand that I am to have the usual and ordinary care practiced by physicians
and surgeons and furnished by hospitals in this community and that no other promise or
representation, written or implied, is made, nor is any employee or representative o f the
hospital authorized to make any other promise or representation.

6.

I consent to the administration o f sedation and/or anesthesia prescribed or chosen by the
attending physician and/or surgeon and/or anesthesiologist

7.

I consent to photographs for educational purposes, provided my identity is not revealed, as
my physician desires. I also consent to medical trainees being present in the room to observe
for educational purposes.

8.

I hereby authorize Ferguson Hospital to retain, preserve, and use for scientific or teaching
purposes any specimen or tissue taken from my body.

9.

I consent to the disposal by authorities of the Ferguson Hospital of any tissue or part which
m aybe removed.

10.

I ACKNOWLEDGE THAT I HAVE READ AND FULLY UNDERSTAND THE ABOVE
CONSENT.

Signed_________________________
(patient)

W itness_______________________________
AM

Date signed_______________ Time_______ p m

o r _________________________
(parent, guardian, other)
___________________________________
R elationship to P atient

0-18-601 (3/84)
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Blodgett
MEMORIAL M EDICA L CENTER

MEMORANDUM
TO:
FROM :

Jennifer Thebo

' P u f f e r y Ursul, General Counsel/D irector o f A dm inistrative Services

DA TE:

M arch 18, 1998

RE:

IRB EXCLUSION STA TEM EN T

I am in receipt o f your memo dated M arch 17, 1998 regarding y o u r research study entitled.
“M olecular Staging o f Colorectal Cancer: K-ras Mutation A nalysis o f L ym ph Nodes Upstages
D ukes' B- P atien ts.” Because o f the fact that this study utilizes archived m aterial and
previously collected patient data, it is not necessary for you to obtain IRB approval.
I f I can be o f any further assistance to you, please do not hesitate to co n tact m e at 391-2729.
M LU /csd

Cm$faTk
Community

1840 W ealthy SE

G rina Rapids Ml 49506-2968

616-774-7444
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